

**Clinical trial results:****A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with Durvalumab versus Nivolumab Monotherapy in Subjects with Select Advanced Malignancies
Summary**

EudraCT number	2016-000323-43
Trial protocol	GB NL
Global end of trial date	17 March 2020

Results information

Result version number	v2 (current)
This version publication date	26 May 2021
First version publication date	20 March 2021
Version creation reason	

Trial information**Trial identification**

Sponsor protocol code	D6020C00001
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02118337
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	MedImmune, LLC
Sponsor organisation address	One MedImmune Way, Gaithersburg, United States, 20878
Public contact	Farzana Walcott, MedImmune, LLC, +1 3013983063, information.center@astrazeneca.com
Scientific contact	Farzana Walcott, MedImmune, LLC, +1 3013983063, information.center@astrazeneca.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	30 October 2020
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	17 March 2020
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main objectives of the study are as below:

1. For dose-escalation phase: To determine safety profile of of MEDI0680 in combination with durvalumab in participants with select advanced malignancies.
2. For dose-expansion: To evaluate the antitumor activity of MEDI0680 in combination with durvalumab versus nivolumab monotherapy in immunotherapy naïve participants with advanced or metastatic clear cell renal cell carcinoma (ccRCC) as based on investigator assessed response using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

Protection of trial subjects:

The conduct of this clinical study met all local and regulatory requirements. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and are consistent with International Conference on Harmonization guideline: Good Clinical Practice, and applicable regulatory requirements. Participants signed an informed consent form and could withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Only investigators qualified by training and experience were selected as appropriate experts to investigate the study drug.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	19 May 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 7
Country: Number of subjects enrolled	Canada: 5
Country: Number of subjects enrolled	France: 8
Country: Number of subjects enrolled	Netherlands: 8
Country: Number of subjects enrolled	United Kingdom: 3
Country: Number of subjects enrolled	United States: 66
Worldwide total number of subjects	97
EEA total number of subjects	16

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	56
From 65 to 84 years	40
85 years and over	1

Subject disposition

Recruitment

Recruitment details:

The study is conducted in Australia, Canada, France, Netherlands, United Kingdom, and the United States.

Pre-assignment

Screening details:

Of the 130 participants screened, 97 participants were enrolled and were treated in this study.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	MEDI0680 0.1 mg/kg + Durvalumab 3 mg

Arm description:

Participants in dose-escalation phase received IV infusion of MEDI0680 0.1 mg/kg and durvalumab 3 mg/kg every 2 weeks (Q2W) for up to 12 months.

Arm type	Experimental
Investigational medicinal product name	MEDI0680
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous (IV) infusion of MEDI0680 0.1 mg/kg Q2W for up to 12 months.

Investigational medicinal product name	Durvalumab
Investigational medicinal product code	MEDI4736
Other name	
Pharmaceutical forms	Powder and solvent for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

IV infusion of durvalumab 3 mg Q2W for up to 12 months.

Arm title	MEDI0680 0.1 mg/kg + Durvalumab 10 mg
------------------	---------------------------------------

Arm description:

Participants in dose-escalation phase received IV infusion of MEDI0680 0.1 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.

Arm type	Experimental
Investigational medicinal product name	MEDI0680
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

IV infusion of MEDI0680 0.1 mg/kg Q2W for up to 12 months.

Investigational medicinal product name	Durvalumab
Investigational medicinal product code	MEDI4736
Other name	
Pharmaceutical forms	Powder and solvent for solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
IV infusion of durvalumab 10 mg Q2W for up to 12 months.	
Arm title	MEDI0680 0.5 mg/kg + Durvalumab 10 mg
Arm description:	
Participants in dose-escalation phase received IV infusion of MEDI0680 0.5 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.	
Arm type	Experimental
Investigational medicinal product name	MEDI0680
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
IV infusion of MEDI0680 0.5 mg/kg Q2W for up to 12 months.	
Investigational medicinal product name	Durvalumab
Investigational medicinal product code	MEDI4736
Other name	
Pharmaceutical forms	Powder and solvent for solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
IV infusion of durvalumab 10 mg Q2W for up to 12 months.	
Arm title	MEDI0680 2.5 mg/kg + Durvalumab 10 mg
Arm description:	
Participants in dose-escalation phase received IV infusion of MEDI0680 2.5 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.	
Arm type	Experimental
Investigational medicinal product name	MEDI0680
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
IV infusion of MEDI0680 2.5 mg/kg Q2W for up to 12 months.	
Investigational medicinal product name	Durvalumab
Investigational medicinal product code	MEDI4736
Other name	
Pharmaceutical forms	Powder and solvent for solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
IV infusion of durvalumab 10 mg Q2W for up to 12 months.	
Arm title	MEDI0680 10 mg/kg + Durvalumab 10 mg
Arm description:	
Participants in dose-escalation phase received IV infusion of MEDI0680 10 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.	
Arm type	Experimental

Investigational medicinal product name	MEDI0680
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

IV infusion of MEDI0680 10 mg/kg Q2W for up to 12 months.

Investigational medicinal product name	Durvalumab
Investigational medicinal product code	MEDI4736
Other name	
Pharmaceutical forms	Powder and solvent for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

IV infusion of durvalumab 10 mg Q2W for up to 12 months.

Arm title	MEDI0680 20 mg/kg + Durvalumab 10 mg
------------------	--------------------------------------

Arm description:

Participants in dose-escalation phase received IV infusion of MEDI0680 20 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.

Arm type	Experimental
Investigational medicinal product name	MEDI0680
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

IV infusion of MEDI0680 20 mg/kg Q2W for up to 12 months

Investigational medicinal product name	Durvalumab
Investigational medicinal product code	MEDI4736
Other name	
Pharmaceutical forms	Powder and solvent for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

IV infusion of durvalumab 10 mg Q2W for up to 12 months.

Arm title	MEDI0680 20 mg/kg
------------------	-------------------

Arm description:

Participants in dose-expansion phase received IV infusion of MEDI0680 20 mg/kg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.

Arm type	Experimental
Investigational medicinal product name	MEDI0680
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

IV infusion of MEDI0680 20 mg/kg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.

Arm title	MEDI0680 20 mg/kg + Durvalumab 750 mg
------------------	---------------------------------------

Arm description:

Participants in dose-expansion phase received IV infusion of MEDI0680 20 mg/kg and durvalumab 750 mg/kg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.

Arm type	Experimental
Investigational medicinal product name	MEDI0680
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

IV infusion of MEDI0680 20 mg/kg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.

Investigational medicinal product name	Durvalumab
Investigational medicinal product code	MEDI4736
Other name	
Pharmaceutical forms	Powder and solvent for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

IV infusion of durvalumab 750 mg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.

Arm title	Nivolumab 240 mg
------------------	------------------

Arm description:

Participants in dose-expansion phase received IV infusion of nivolumab 240 mg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.

Arm type	Experimental
Investigational medicinal product name	Nivolumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

IV infusion of nivolumab 240 mg/kg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.

Number of subjects in period 1	MEDI0680 0.1 mg/kg + Durvalumab 3 mg	MEDI0680 0.1 mg/kg + Durvalumab 10 mg	MEDI0680 0.5 mg/kg + Durvalumab 10 mg
Started	4	5	3
Completed	0	0	0
Not completed	4	5	3
Consent withdrawn by subject	1	3	2
Death	2	2	1
Unspecified	1	-	-
Lost to follow-up	-	-	-

Number of subjects in period 1	MEDI0680 2.5 mg/kg + Durvalumab 10 mg	MEDI0680 10 mg/kg + Durvalumab 10 mg	MEDI0680 20 mg/kg + Durvalumab 10 mg
Started	3	9	6

Completed	0	0	0
Not completed	3	9	6
Consent withdrawn by subject	1	2	2
Death	2	5	1
Unspecified	-	2	3
Lost to follow-up	-	-	-

Number of subjects in period 1	MEDI0680 20 mg/kg	MEDI0680 20 mg/kg + Durvalumab 750 mg	Nivolumab 240 mg
Started	4	42	21
Completed	0	0	0
Not completed	4	42	21
Consent withdrawn by subject	1	4	2
Death	2	9	4
Unspecified	1	28	15
Lost to follow-up	-	1	-

Baseline characteristics

Reporting groups

Reporting group title	MEDI0680 0.1 mg/kg + Durvalumab 3 mg
Reporting group description: Participants in dose-escalation phase received IV infusion of MEDI0680 0.1 mg/kg and durvalumab 3 mg/kg every 2 weeks (Q2W) for up to 12 months.	
Reporting group title	MEDI0680 0.1 mg/kg + Durvalumab 10 mg
Reporting group description: Participants in dose-escalation phase received IV infusion of MEDI0680 0.1 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.	
Reporting group title	MEDI0680 0.5 mg/kg + Durvalumab 10 mg
Reporting group description: Participants in dose-escalation phase received IV infusion of MEDI0680 0.5 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.	
Reporting group title	MEDI0680 2.5 mg/kg + Durvalumab 10 mg
Reporting group description: Participants in dose-escalation phase received IV infusion of MEDI0680 2.5 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.	
Reporting group title	MEDI0680 10 mg/kg + Durvalumab 10 mg
Reporting group description: Participants in dose-escalation phase received IV infusion of MEDI0680 10 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.	
Reporting group title	MEDI0680 20 mg/kg + Durvalumab 10 mg
Reporting group description: Participants in dose-escalation phase received IV infusion of MEDI0680 20 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.	
Reporting group title	MEDI0680 20 mg/kg
Reporting group description: Participants in dose-expansion phase received IV infusion of MEDI0680 20 mg/kg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.	
Reporting group title	MEDI0680 20 mg/kg + Durvalumab 750 mg
Reporting group description: Participants in dose-expansion phase received IV infusion of MEDI0680 20 mg/kg and durvalumab 750 mg/kg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.	
Reporting group title	Nivolumab 240 mg
Reporting group description: Participants in dose-expansion phase received IV infusion of nivolumab 240 mg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.	

Reporting group values	MEDI0680 0.1 mg/kg + Durvalumab 3 mg	MEDI0680 0.1 mg/kg + Durvalumab 10 mg	MEDI0680 0.5 mg/kg + Durvalumab 10 mg
Number of subjects	4	5	3
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0

Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	2	2	2
From 65-84 years	2	3	1
85 years and over	0	0	0
Age Continuous Units: years			
arithmetic mean	60.5	67.4	52.3
standard deviation	± 12.6	± 8.4	± 17.9
Sex: Female, Male Units: Participants			
Female	1	3	1
Male	3	2	2
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	1	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	4	4	3
More than one race	0	0	0
Unknown or Not Reported	0	0	0
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	1	0	1
Not Hispanic or Latino	3	5	2
Unknown or Not Reported	0	0	0

Reporting group values	MEDI0680 2.5 mg/kg + Durvalumab 10 mg	MEDI0680 10 mg/kg + Durvalumab 10 mg	MEDI0680 20 mg/kg + Durvalumab 10 mg
Number of subjects	3	9	6
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	2	7	1
From 65-84 years	1	1	5
85 years and over	0	1	0
Age Continuous Units: years			
arithmetic mean	62.3	62.1	69.5
standard deviation	± 11.6	± 11.0	± 9.9

Sex: Female, Male			
Units: Participants			
Female	1	5	2
Male	2	4	4
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	1	0
Black or African American	0	0	0
White	2	8	6
More than one race	0	0	0
Unknown or Not Reported	1	0	0
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	0	2	0
Not Hispanic or Latino	2	7	6
Unknown or Not Reported	1	0	0

Reporting group values	MEDI0680 20 mg/kg	MEDI0680 20 mg/kg + Durvalumab 750 mg	Nivolumab 240 mg
Number of subjects	4	42	21
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	2	21	17
From 65-84 years	2	21	4
85 years and over	0	0	0
Age Continuous			
Units: years			
arithmetic mean	64.8	61.0	59.1
standard deviation	± 14.2	± 9.8	± 10.5
Sex: Female, Male			
Units: Participants			
Female	1	9	6
Male	3	33	15
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	1	0	0
Asian	0	1	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	3
White	3	34	16
More than one race	0	0	0

Unknown or Not Reported	0	7	2
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	0	1	1
Not Hispanic or Latino	4	40	20
Unknown or Not Reported	0	1	0

Reporting group values	Total		
Number of subjects	97		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	56		
From 65-84 years	40		
85 years and over	1		
Age Continuous			
Units: years			
arithmetic mean			
standard deviation	-		
Sex: Female, Male			
Units: Participants			
Female	29		
Male	68		
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	1		
Asian	2		
Native Hawaiian or Other Pacific Islander	1		
Black or African American	3		
White	80		
More than one race	0		
Unknown or Not Reported	10		
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	6		
Not Hispanic or Latino	89		
Unknown or Not Reported	2		

End points

End points reporting groups

Reporting group title	MEDI0680 0.1 mg/kg + Durvalumab 3 mg
Reporting group description: Participants in dose-escalation phase received IV infusion of MEDI0680 0.1 mg/kg and durvalumab 3 mg/kg every 2 weeks (Q2W) for up to 12 months.	
Reporting group title	MEDI0680 0.1 mg/kg + Durvalumab 10 mg
Reporting group description: Participants in dose-escalation phase received IV infusion of MEDI0680 0.1 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.	
Reporting group title	MEDI0680 0.5 mg/kg + Durvalumab 10 mg
Reporting group description: Participants in dose-escalation phase received IV infusion of MEDI0680 0.5 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.	
Reporting group title	MEDI0680 2.5 mg/kg + Durvalumab 10 mg
Reporting group description: Participants in dose-escalation phase received IV infusion of MEDI0680 2.5 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.	
Reporting group title	MEDI0680 10 mg/kg + Durvalumab 10 mg
Reporting group description: Participants in dose-escalation phase received IV infusion of MEDI0680 10 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.	
Reporting group title	MEDI0680 20 mg/kg + Durvalumab 10 mg
Reporting group description: Participants in dose-escalation phase received IV infusion of MEDI0680 20 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.	
Reporting group title	MEDI0680 20 mg/kg
Reporting group description: Participants in dose-expansion phase received IV infusion of MEDI0680 20 mg/kg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.	
Reporting group title	MEDI0680 20 mg/kg + Durvalumab 750 mg
Reporting group description: Participants in dose-expansion phase received IV infusion of MEDI0680 20 mg/kg and durvalumab 750 mg/kg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.	
Reporting group title	Nivolumab 240 mg
Reporting group description: Participants in dose-expansion phase received IV infusion of nivolumab 240 mg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.	

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) in Dose-escalation Phase

End point title	Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) in Dose-escalation Phase ^{[1][2]}
-----------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------

End point description:

An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that

worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug. As-treated population (participants who received any study drug [MEDI0680, durvalumab, or nivolumab] and grouped according to actual treatment received) was analysed for this end point.

End point type	Primary
End point timeframe:	
Day 1 through 90 days post end of treatment (approximately 5 years 10 months)	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for the end points.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 0.1 mg/kg + Durvalumab 3 mg	MEDI0680 0.1 mg/kg + Durvalumab 10 mg	MEDI0680 0.5 mg/kg + Durvalumab 10 mg	MEDI0680 2.5 mg/kg + Durvalumab 10 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	5	3	3
Units: Participants				
Any TEAE	4	5	3	3
Any TESA	1	1	1	2

End point values	MEDI0680 10 mg/kg + Durvalumab 10 mg	MEDI0680 20 mg/kg + Durvalumab 10 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	6		
Units: Participants				
Any TEAE	9	6		
Any TESA	6	0		

Statistical analyses

No statistical analyses for this end point

Primary: Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose-escalation Phase

End point title	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose-escalation Phase ^[3] ^[4]
-----------------	----------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Number of participants in dose-escalation phase with abnormal clinical laboratory parameters reported as TEAEs are reported. Abnormal clinical laboratory parameters are defined as any abnormal finding during analysis of serum chemistry, hematology, coagulation, and urine. As-treated population (participants who received any study drug [MEDI0680, durvalumab, or nivolumab] and grouped according to actual treatment received) was analysed for this end point.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 through 90 days post end of treatment (approximately 5 years 10 months)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for the end points.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 0.1 mg/kg + Durvalumab 3 mg	MEDI0680 0.1 mg/kg + Durvalumab 10 mg	MEDI0680 0.5 mg/kg + Durvalumab 10 mg	MEDI0680 2.5 mg/kg + Durvalumab 10 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	5	3	3
Units: Participants				
Anaemia	0	0	1	1
Iron deficiency anaemia	0	0	0	0
Leukocytosis	1	0	0	0
Lymphopenia	0	0	0	0
Activated partial thromboplastin time prolonged	0	0	0	0
Blood fibrinogen decreased	1	0	0	0
International normalized ratio	0	0	0	0
Lymphocyte count decreased	0	0	0	0
Prothrombin time prolonged	0	0	0	0
White blood cell count decreased	0	0	0	0
Alanine aminotransferase increased	0	0	0	0
Amylase increased	0	0	0	0
Aspartate aminotransferase increased	0	0	0	0
Blood alkaline phosphatase increased	1	0	1	0
Blood creatinine increased	0	0	0	0
Blood phosphorus decreased	1	0	0	0
Blood urea increased	0	0	0	0
Gamma glutamyltransferase increased	0	0	0	0
Lipase increased	1	0	1	0
Hypercalcaemia	0	0	0	0
Hyperglycaemia	0	0	0	0
Hyperkalaemia	0	0	0	0
Hypermagnesaemia	0	0	1	0
Hyperuricaemia	1	0	0	0
Hypoalbuminaemia	0	0	0	0
Hypokalaemia	0	0	0	0
Hypomagnesaemia	0	0	0	0
Hyponatraemia	0	0	0	0
proteinuria	0	0	0	0

End point values	MEDI0680 10 mg/kg + Durvalumab 10	MEDI0680 20 mg/kg + Durvalumab 10		
------------------	-----------------------------------	-----------------------------------	--	--

	mg	mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	6		
Units: Participants				
Anaemia	3	0		
Iron deficiency anaemia	1	0		
Leukocytosis	0	0		
Lymphopenia	1	0		
Activated partial thromboplastin time prolonged	0	1		
Blood fibrinogen decreased	0	1		
International normalized ratio	0	1		
Lymphocyte count decreased	0	1		
Prothrombin time prolonged	0	1		
White blood cell count decreased	0	1		
Alanine aminotransferase increased	1	0		
Amylase increased	1	1		
Aspartate aminotransferase increased	2	0		
Blood alkaline phosphatase increased	1	0		
Blood creatinine increased	2	1		
Blood phosphorus decreased	0	0		
Blood urea increased	1	0		
Gamma glutamyltransferase increased	1	0		
Lipase increased	1	0		
Hypercalcaemia	1	1		
Hyperglycaemia	1	0		
Hyperkalaemia	1	0		
Hypermagnesaemia	0	0		
Hyperuricaemia	1	0		
Hypoalbuminaemia	1	0		
Hypokalaemia	2	0		
Hypomagnesaemia	2	0		
Hyponatraemia	2	1		
proteinuria	1	0		

Statistical analyses

No statistical analyses for this end point

Primary: Number of Participants With Abnormal Vital Signs and Physical Examinations Reported as TEAES in Dose-escalation Phase

End point title	Number of Participants With Abnormal Vital Signs and Physical Examinations Reported as TEAES in Dose-escalation Phase ^{[5][6]}
-----------------	-----------------------------------------------------------------------------------------------------------------------------------------

End point description:

Number of participants in dose-escalation phase with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs is defined as any abnormal finding in the vital sign parameters (blood pressure, heart rate, body temperature, and respiratory rate). Abnormal physical examination findings are defined as any abnormal finding in the following body systems: head and neck, respiratory, cardiovascular, gastrointestinal, urogenital, musculoskeletal, neurological, psychiatric, dermatological, hematologic/lymphatic, and endocrine systems, and weight. As-treated population (participants who received any study drug [MEDI0680, durvalumab, or nivolumab] and grouped according to actual treatment received) was analysed for this end point.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 through 90 days post end of treatment (approximately 5 years 10 months)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for the end points.

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 0.1 mg/kg + Durvalumab 3 mg	MEDI0680 0.1 mg/kg + Durvalumab 10 mg	MEDI0680 0.5 mg/kg + Durvalumab 10 mg	MEDI0680 2.5 mg/kg + Durvalumab 10 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	5	3	3
Units: Participants				
Atrial fibrillation	0	0	0	0
Palpitations	1	0	0	0
Sinus tachycardia	0	0	0	0
Tachycardia	0	0	0	0
Pyrexia	0	0	2	0
Weight decreased	0	0	0	0
Hypertension	1	0	0	0

End point values	MEDI0680 10 mg/kg + Durvalumab 10 mg	MEDI0680 20 mg/kg + Durvalumab 10 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	6		
Units: Participants				
Atrial fibrillation	1	0		
Palpitations	0	0		
Sinus tachycardia	1	0		
Tachycardia	0	1		
Pyrexia	3	1		
Weight decreased	1	1		
Hypertension	1	1		

Statistical analyses

No statistical analyses for this end point

Primary: Number of Participants With Abnormal Electrocardiograms (ECGs) Reported as TEAEs in Dose-escalation Phase

End point title	Number of Participants With Abnormal Electrocardiograms (ECGs) Reported as TEAEs in Dose-escalation Phase ^{[7][8]}
-----------------	-----------------------------------------------------------------------------------------------------------------------------

End point description:

Number of participants in dose-escalation phase with abnormal ECG parameters reported as TEAEs are reported. As-treated population (participants who received any study drug [MEDI0680, durvalumab, or nivolumab] and grouped according to actual treatment received) was analysed for this end point.

End point type Primary

End point timeframe:

Day 1 through 90 days post end of treatment (approximately 5 years 10 months)

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not applicable since there were no inferential statistics, only descriptive statistics were performed for the end points.

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 0.1 mg/kg + Durvalumab 3 mg	MEDI0680 0.1 mg/kg + Durvalumab 10 mg	MEDI0680 0.5 mg/kg + Durvalumab 10 mg	MEDI0680 2.5 mg/kg + Durvalumab 10 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	5	3	3
Units: Participants				
Palpitations	1	0	0	0
Atrial fibrillation	0	0	0	0
Sinus tachycardia	0	0	0	0
Pericardial effusion	0	0	0	0
Tachycardia	0	0	0	0

End point values	MEDI0680 10 mg/kg + Durvalumab 10 mg	MEDI0680 20 mg/kg + Durvalumab 10 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	6		
Units: Participants				
Palpitations	0	0		
Atrial fibrillation	1	0		
Sinus tachycardia	1	0		
Pericardial effusion	1	0		
Tachycardia	0	1		

Statistical analyses

No statistical analyses for this end point

Primary: Objective Response Rate (ORR) Based on Investigator-assessed Response Using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) in Dose-expansion Phase

End point title Objective Response Rate (ORR) Based on Investigator-

End point description:

The ORR is defined as best overall response of confirmed complete response (CR) or confirmed partial response (PR) based on RECIST v1.1. The CR is defined as disappearance of all target and non-target lesions and no new lesions. The PR is defined as $\geq 30\%$ decrease in the sum of diameters of target lesions (compared to baseline) and no new non-target lesion. A confirmed CR or PR is defined as 2 CRs or 2 PRs that were separated by at least 4 weeks with no evidence of progression in-between. As-treated population was analysed for this end point.

End point type	Primary
----------------	---------

End point timeframe:

From baseline (Day -42 to Day -1) through disease progression or end of treatment (approximately 5 years 10 months)

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 20 mg/kg	MEDI0680 20 mg/kg + Durvalumab 750 mg	Nivolumab 240 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	42	21	
Units: Percentage of participants				
number (confidence interval 95%)	0 (0 to 60.2)	16.7 (7.0 to 31.4)	23.8 (8.2 to 47.2)	

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	MEDI0680 20 mg/kg v Nivolumab 240 mg
Number of subjects included in analysis	25
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.5494
Method	Fisher exact
Parameter estimate	Rate difference
Point estimate	-23.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-72.8
upper limit	31.1

Statistical analysis title	Statistical Analysis 2
Comparison groups	MEDI0680 20 mg/kg + Durvalumab 750 mg v Nivolumab 240 mg

Number of subjects included in analysis	63
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.513
Method	Fisher exact
Parameter estimate	Rate difference
Point estimate	-7.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-33.6
upper limit	20

Secondary: Best Overall Response (BOR) Based on Investigator-assessed RECIST v1.1 in Dose-expansion Phase

End point title	Best Overall Response (BOR) Based on Investigator-assessed RECIST v1.1 in Dose-expansion Phase ^[10]
-----------------	----------------------------------------------------------------------------------------------------------------

End point description:

The BOR includes CR, PR, stable disease (SD), progressive disease (PD), and non-evaluable (NE) based on RECIST v1.1. The CR is defined as disappearance of all target and non-target lesions and no new lesions. The PR is defined as $\geq 30\%$ decrease in the sum of diameters of target lesions (compared to baseline) and no new nontarget lesion. The PD is defined at least 20% decrease in the sum of diameters of target lesions (compared to baseline) and/or new lesion. The SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression. The NE is defined as either when no or only a subset of lesion measurements are made at an assessment. As-treated population was analysed for this end point.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline (Day -42 to Day -1) through disease progression or end of treatment (approximately 5 years 10 months)

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 20 mg/kg	MEDI0680 20 mg/kg + Durvalumab 750 mg	Nivolumab 240 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	42	21	
Units: Participants				
CR	0	2	0	
PR	0	5	5	
SD	3	17	8	
PD	1	17	6	
NE	0	1	2	

Statistical analyses

Secondary: Disease Control Rate (DCR) Based on Investigator-assessed RECIST v1.1 in Dose-expansion Phase

End point title	Disease Control Rate (DCR) Based on Investigator-assessed RECIST v1.1 in Dose-expansion Phase ^[11]
-----------------	---------------------------------------------------------------------------------------------------------------

End point description:

The DCR is defined as a BOR of confirmed CR, confirmed PR, or SD based on RECIST v1.1. A confirmed CR is defined as two CRs (disappearance of all target and non-target lesions and no new lesions) that were separated by at least 4 weeks with no evidence of progression in-between. A confirmed PR is defined as two PRs ($\geq 30\%$ decrease in the sum of diameters of target lesions compared to baseline and no new non-target lesion) that were separated by at least 4 weeks with no evidence of progression in-between. The SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression. The DCR at ≥ 8 weeks and ≥ 24 weeks are reported. As-treated population was analysed for this end point.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline (Day -42 to Day -1) through disease progression or end of treatment (approximately 5 years 10 months)

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 20 mg/kg	MEDI0680 20 mg/kg + Durvalumab 750 mg	Nivolumab 240 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	42	21	
Units: Percentage of participants				
number (confidence interval 95%)				
DCR at ≥ 8 weeks	75.0 (19.4 to 99.4)	57.1 (41.0 to 72.3)	61.9 (38.4 to 81.9)	
DCR at ≥ 24 weeks	50.0 (6.8 to 93.2)	38.1 (23.6 to 54.4)	38.1 (18.1 to 61.6)	

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Response (TTR) Based on Investigator-assessed RECIST v1.1 in Dose-expansion Phase

End point title	Time to Response (TTR) Based on Investigator-assessed RECIST v1.1 in Dose-expansion Phase ^[12]
-----------------	-----------------------------------------------------------------------------------------------------------

End point description:

The TTR is defined as the time from the first dose of treatment until the first documentation of a subsequently confirmed OR (confirmed CR or confirmed PR) based on RECIST v1.1. A confirmed CR is defined as two CRs (disappearance of all target and non-target lesions and no new lesions) that were separated by at least 4 weeks with no evidence of progression in-between. A confirmed PR is defined as two PRs ($\geq 30\%$ decrease in the sum of diameters of target lesions compared to baseline and no new non-target lesion) that were separated by at least 4 weeks with no evidence of progression in-between. The TTR was estimated using Kaplan-Meier method. The TTR was analysed for participants from As-treated population who achieved OR.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline (Day -42 to Day -1) through disease progression or end of treatment (approximately 5 years 10 months)

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 20 mg/kg	MEDI0680 20 mg/kg + Durvalumab 750 mg	Nivolumab 240 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0 ^[13]	7	5	
Units: Months				
median (confidence interval 95%)	(to)	1.8 (1.7 to 9.1)	1.8 (1.6 to 7.3)	

Notes:

[13] - No participant had achieved OR.

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of Response (DoR) Based on Investigator-assessed RECIST v1.1 in Dose-expansion Phase

End point title	Duration of Response (DoR) Based on Investigator-assessed RECIST v1.1 in Dose-expansion Phase ^[14]
-----------------	---------------------------------------------------------------------------------------------------------------

End point description:

The DoR is defined as duration from the first documentation of OR (confirmed CR or confirmed PR) to the first documented disease progression based on RECIST v1.1 or death due to any cause, whichever occurred first. The confirmed CR or confirmed PR means 2 CRs (disappearance of all target and non-target lesions and no new lesions) or 2 PRs ($\geq 30\%$ decrease in the sum of diameters of target lesions compared to baseline and no new non-target lesion) that were separated by at least 4 weeks with no evidence of progression in-between; and PD means at least 20% decrease in the sum of diameters of target lesions (compared to baseline) and/or new lesion. The DoR was estimated using Kaplan-Meier method. The arbitrary numbers 99.999 and 99999 signified the data for median and upper limit of confidence interval could not be derived due to insufficient events being observed at the time of the analysis. The DoR was analysed for participants from As-treated population who achieved OR.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline (Day -42 to Day -1) through disease progression or end of treatment (approximately 5 years 10 months)

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 20 mg/kg	MEDI0680 20 mg/kg + Durvalumab 750 mg	Nivolumab 240 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0 ^[15]	7	5	
Units: Months				
median (confidence interval 95%)	(to)	99.999 (12.9 to 99999)	99.999 (4.4 to 99999)	

Notes:

[15] - No participant had achieved OR in this arm.

Statistical analyses

No statistical analyses for this end point

Secondary: Progression Free Survival (PFS) Based on Investigator-assessed RECIST v1.1 in Dose-expansion Phase

End point title	Progression Free Survival (PFS) Based on Investigator-assessed RECIST v1.1 in Dose-expansion Phase ^[16]
-----------------	--------------------------------------------------------------------------------------------------------------------

End point description:

The PFS is defined as the time from the start of study treatment until the first documentation of disease progression based on RECIST v1.1 or death due to any cause, whichever occurred first. The PFS was estimated using Kaplan-Meier method. As-treated population (participants who received any study drug [MEDI0680, durvalumab, or nivolumab] and grouped according to actual treatment received) was analysed for this end point.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline (Day -42 to Day -1) through disease progression or end of treatment (approximately 5 years 10 months)

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 20 mg/kg	MEDI0680 20 mg/kg + Durvalumab 750 mg	Nivolumab 240 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	42	21	
Units: Months				
median (confidence interval 95%)	5.5 (2.2 to 7.4)	3.6 (2.0 to 5.5)	3.6 (1.9 to 13.0)	

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Survival in Dose-expansion Phase

End point title	Overall Survival in Dose-expansion Phase ^[17]
-----------------	----------------------------------------------------------

End point description:

The OS is defined as the time from the start of study treatment until death due to any cause. The OS was estimated using Kaplan-Meier method. The arbitrary numbers 99.999, 0.9999, and 99999 signified the data for median, and lower and upper limit of confidence interval could not be derived due to insufficient number of events being observed at the time of the analysis. As-treated population (participants who received any study drug [MEDI0680, durvalumab, or nivolumab] and grouped according to actual treatment received) was analysed for this end point.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline (Day -42 to Day -1) through disease progression or end of treatment (approximately 5 years 10 months)

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 20 mg/kg	MEDI0680 20 mg/kg + Durvalumab 750 mg	Nivolumab 240 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	42	21	
Units: Months				
median (confidence interval 95%)	19.9 (7.0 to 19.9)	99.999 (0.9999 to 99999)	99.999 (12.0 to 99999)	

Statistical analyses

No statistical analyses for this end point

Secondary: BOR Based on Investigator-assessed Modified RECIST v1.1 in Dose-escalation Phase

End point title	BOR Based on Investigator-assessed Modified RECIST v1.1 in Dose-escalation Phase ^[18]
-----------------	--------------------------------------------------------------------------------------------------

End point description:

The BOR includes CR, PR, SD, PD, and NE per Modified RECIST v1.1. The CR is defined as disappearance of all target and non-target lesions and no new lesions. The PR is defined as $\geq 30\%$ decrease in the sum of diameters of target lesions (compared to baseline) and no new nontarget lesion. The PD is defined at least 20% decrease in the sum of diameters of target lesions (compared to baseline) and/or new lesion. The SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression. The NE is defined as either when no or only a subset of lesion measurements are made at an assessment. As-treated population was analysed for this end point.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline (Day -42 to Day -1) through disease progression or EOT (approximately 12 months for each participant)

Notes:

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 0.1 mg/kg + Durvalumab 3 mg	MEDI0680 0.1 mg/kg + Durvalumab 10 mg	MEDI0680 0.5 mg/kg + Durvalumab 10 mg	MEDI0680 2.5 mg/kg + Durvalumab 10 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	5	3	3
Units: Participants				
CR	0	0	0	0
PR	2	0	1	0
SD	1	1	0	1
PD	1	3	2	1
NE	0	1	0	1

End point values	MEDI0680 10 mg/kg + Durvalumab 10 mg	MEDI0680 20 mg/kg + Durvalumab 10 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	6		
Units: Participants				
CR	1	0		
PR	3	4		
SD	2	1		
PD	2	1		
NE	1	0		

Statistical analyses

No statistical analyses for this end point

Secondary: ORR Based on Investigator-assessed Modified RECIST v1.1 in Dose-escalation Phase

End point title	ORR Based on Investigator-assessed Modified RECIST v1.1 in Dose-escalation Phase ^[19]
-----------------	--------------------------------------------------------------------------------------------------

End point description:

The ORR is defined as best overall response of confirmed CR or confirmed PR based on modified RECIST v1.1. The CR is defined as disappearance of all target and non-target lesions and no new lesions. The PR is defined as $\geq 30\%$ decrease in the sum of diameters of target lesions (compared to baseline) and no new non-target lesion. A confirmed CR or PR is defined as 2 CRs or 2 PRs that were separated by at least 4 weeks with no evidence of progression in-between. As-treated population was analysed for this end point.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline (Day -42 to Day -1) through disease progression or EOT (approximately 12 months for each participant)

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 0.1 mg/kg + Durvalumab 3 mg	MEDI0680 0.1 mg/kg + Durvalumab 10 mg	MEDI0680 0.5 mg/kg + Durvalumab 10 mg	MEDI0680 2.5 mg/kg + Durvalumab 10 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	5	3	3
Units: Percentage of participants				
number (confidence interval 95%)	50.0 (6.8 to 93.2)	0 (0 to 52.2)	33.3 (0.8 to 90.6)	0 (0 to 70.8)

End point values	MEDI0680 10 mg/kg + Durvalumab 10 mg	MEDI0680 20 mg/kg + Durvalumab 10 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	6		
Units: Percentage of participants				
number (confidence interval 95%)	44.4 (13.7 to 78.8)	66.7 (22.3 to 95.7)		

Statistical analyses

No statistical analyses for this end point

Secondary: DCR Based on Investigator-assessed Modified RECIST v1.1 in Dose-escalation Phase

End point title	DCR Based on Investigator-assessed Modified RECIST v1.1 in Dose-escalation Phase ^[20]
-----------------	--------------------------------------------------------------------------------------------------

End point description:

The DCR is defined as a BOR of confirmed CR, confirmed PR, or SD based on modified RECIST v1.1. A confirmed CR is defined as two CRs (disappearance of all target and non-target lesions and no new lesions) that were separated by at least 4 weeks with no evidence of progression in-between. A confirmed PR is defined as two PRs ($\geq 30\%$ decrease in the sum of diameters of target lesions compared to baseline and no new non-target lesion) that were separated by at least 4 weeks with no evidence of progression in-between. The SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression. The DCR at ≥ 8 weeks and ≥ 24 weeks are reported. As-treated population was analysed for this end point.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline (Day -42 to Day -1) through disease progression or EOT (approximately 12 months for each participant)

Notes:

[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 0.1 mg/kg + Durvalumab 3 mg	MEDI0680 0.1 mg/kg + Durvalumab 10 mg	MEDI0680 0.5 mg/kg + Durvalumab 10 mg	MEDI0680 2.5 mg/kg + Durvalumab 10 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	5	3	3
Units: Percentage of participants				
number (confidence interval 95%)				
DCR at >= 8 weeks	75.0 (19.4 to 99.4)	20.0 (0.5 to 71.6)	33.3 (0.8 to 90.6)	33.3 (0.8 to 90.6)
DCR at >= 24 weeks	50.0 (6.8 to 93.2)	0 (0 to 52.2)	33.3 (0.8 to 90.6)	0 (0 to 70.8)

End point values	MEDI0680 10 mg/kg + Durvalumab 10 mg	MEDI0680 20 mg/kg + Durvalumab 10 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	6		
Units: Percentage of participants				
number (confidence interval 95%)				
DCR at >= 8 weeks	66.7 (29.9 to 92.5)	83.3 (35.9 to 99.6)		
DCR at >= 24 weeks	44.4 (13.7 to 78.8)	83.3 (35.9 to 99.6)		

Statistical analyses

No statistical analyses for this end point

Secondary: TTR Based on Investigator-assessed Modified RECIST v1.1 in Dose-escalation Phase

End point title	TTR Based on Investigator-assessed Modified RECIST v1.1 in Dose-escalation Phase ^[21]
-----------------	--------------------------------------------------------------------------------------------------

End point description:

The TTR is defined as time from the first dose of treatment until the first documentation of a subsequently confirmed OR (confirmed CR or confirmed PR) based on modified RECIST v1.1. Confirmed CR or confirmed PR are defined as 2 CRs (disappearance of all target and non-target lesions and no new lesions) or 2 PRs (>= 30% decrease in the sum of diameters of target lesions compared to baseline and no new non-target lesion) that were separated by at least 4 weeks with no evidence of progression in-between. The TTR was estimated using Kaplan-Meier method. As-treated population was analysed for this end point. The arbitrary numbers 0.9999 and 99999 signified the data for lower and upper limit of confidence interval could not be derived due to insufficient number of events being observed at the time of the analysis. The TTR was analysed for participants from As-treated population who achieved OR.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline (Day -42 to Day -1) through disease progression or EOT (approximately 12 months for each participant)

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 0.1 mg/kg + Durvalumab 3 mg	MEDI0680 0.1 mg/kg + Durvalumab 10 mg	MEDI0680 0.5 mg/kg + Durvalumab 10 mg	MEDI0680 2.5 mg/kg + Durvalumab 10 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	2	0 ^[22]	1	0 ^[23]
Units: Months				
median (confidence interval 95%)	2.6 (1.6 to 3.5)	(to)	3.4 (0.9999 to 99999)	(to)

Notes:

[22] - No participant had achieved OR.

[23] - No participant had achieved OR.

End point values	MEDI0680 10 mg/kg + Durvalumab 10 mg	MEDI0680 20 mg/kg + Durvalumab 10 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4	4		
Units: Months				
median (confidence interval 95%)	3.5 (1.6 to 3.5)	3.2 (1.7 to 10.8)		

Statistical analyses

No statistical analyses for this end point

Secondary: DoR Based on Investigator-assessed Modified RECIST v1.1 in Dose-escalation Phase

End point title	DoR Based on Investigator-assessed Modified RECIST v1.1 in Dose-escalation Phase ^[24]
-----------------	--------------------------------------------------------------------------------------------------

End point description:

The DoR is defined as duration from the first documentation of OR (confirmed CR or confirmed PR) to the first documented disease progression based on RECIST v1.1 or death due to any cause, whichever occurred first. Confirmed CR or confirmed PR are defined as 2 CRs (disappearance of all target and non-target lesions and no new lesions) or 2 PRs ($\geq 30\%$ decrease in the sum of diameters of target lesions compared to baseline and no new non-target lesion) that were separated by at least 4 weeks with no evidence of progression in-between. The DoR was estimated using Kaplan-Meier method. The arbitrary numbers 99.999, 0.9999, and 99999 signified data for median, and lower and upper limit of confidence interval could not be derived due to insufficient number of events being observed at the time of the analysis. The DoR was analysed for participants from As-treated population who achieved OR.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline (Day -42 to Day -1) through disease progression or EOT (approximately 12 months for each participant)

Notes:

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 0.1 mg/kg + Durvalumab 3 mg	MEDI0680 0.1 mg/kg + Durvalumab 10 mg	MEDI0680 0.5 mg/kg + Durvalumab 10 mg	MEDI0680 2.5 mg/kg + Durvalumab 10 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	2	0 ^[25]	1	0 ^[26]
Units: Months				
median (confidence interval 95%)	16.8 (0.9999 to 99999)	(to)	99.999 (0.9999 to 99999)	(to)

Notes:

[25] - No participant had achieved OR.

[26] - No participant had achieved OR.

End point values	MEDI0680 10 mg/kg + Durvalumab 10 mg	MEDI0680 20 mg/kg + Durvalumab 10 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4	4		
Units: Months				
median (confidence interval 95%)	7.4 (5.6 to 99999)	99.999 (5.6 to 99999)		

Statistical analyses

No statistical analyses for this end point

Secondary: PFS Based on Investigator-assessed Modified RECIST v1.1 in Dose-escalation Phase

End point title	PFS Based on Investigator-assessed Modified RECIST v1.1 in Dose-escalation Phase ^[27]
-----------------	--------------------------------------------------------------------------------------------------

End point description:

The PFS is defined as the time from the start of study treatment until the first documentation of disease progression based on modified RECIST v1.1 or death due to any cause, whichever occurred first. The arbitrary number 99999 signified the data for upper limit of confidence interval could not be derived due to insufficient number of events being observed at the time of the analysis. The PFS was estimated using Kaplan-Meier method. As-treated population was analysed for this end point.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline (Day -42 to Day -1) through disease progression or EOT (approximately 12 months for each participant)

Notes:

[27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 0.1 mg/kg + Durvalumab 3 mg	MEDI0680 0.1 mg/kg + Durvalumab 10 mg	MEDI0680 0.5 mg/kg + Durvalumab 10 mg	MEDI0680 2.5 mg/kg + Durvalumab 10 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	5	3	3
Units: Months				
median (confidence interval 95%)	20.2 (1.6 to 20.2)	1.7 (1.6 to 3.5)	1.6 (1.6 to 99999)	1.8 (1.5 to 3.4)

End point values	MEDI0680 10 mg/kg + Durvalumab 10 mg	MEDI0680 20 mg/kg + Durvalumab 10 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	6		
Units: Months				
median (confidence interval 95%)	7.0 (1.6 to 99999)	23.4 (1.8 to 99999)		

Statistical analyses

No statistical analyses for this end point

Secondary: OS in Dose-escalation Phase

End point title	OS in Dose-escalation Phase ^[28]
-----------------	---------------------------------------------

End point description:

The OS is defined as the time from the start of study treatment until death due to any cause. The OS was estimated using Kaplan-Meier method. The arbitrary numbers 99.999, 0.9999, and 99999 signified the data for median, and lower and upper limit of confidence interval could not be derived due to insufficient number of events being observed at the time of the analysis. As-treated population was analysed for this end point.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline (Day -42 to Day -1) through disease progression or EOT (approximately 12 months for each participant)

Notes:

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 0.1 mg/kg + Durvalumab 3 mg	MEDI0680 0.1 mg/kg + Durvalumab 10 mg	MEDI0680 0.5 mg/kg + Durvalumab 10 mg	MEDI0680 2.5 mg/kg + Durvalumab 10 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	5	3	3
Units: Months				
median (confidence interval 95%)	16.3 (3.6 to 99999)	99.999 (4.2 to 99999)	14.7 (0.9999 to 99999)	7.9 (1.5 to 7.9)

End point values	MEDI0680 10 mg/kg + Durvalumab 10 mg	MEDI0680 20 mg/kg + Durvalumab 10 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	6		
Units: Months				
median (confidence interval 95%)	12.8 (3.1 to 99999)	99.999 (29.6 to 99999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With TEAEs and TSEAEs in Dose-expansion Phase

End point title	Number of Participants With TEAEs and TSEAEs in Dose-expansion Phase ^[29]
-----------------	--------------------------------------------------------------------------------------

End point description:

An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug. As-treated population (participants who received any study drug [MEDI0680, durvalumab, or nivolumab] and grouped according to actual treatment received) was analysed for this end point.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 through 90 days post end of treatment (approximately 5 years 10 months)

Notes:

[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 20 mg/kg	MEDI0680 20 mg/kg + Durvalumab 750 mg	Nivolumab 240 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	42	21	
Units: Participants				
Any TEAE	4	42	20	
Any TSEAE	3	22	13	

Statistical analyses

Secondary: Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose-expansion Phase

End point title	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose-expansion Phase ^[30]
-----------------	-------------------------------------------------------------------------------------------------------------------------------

End point description:

Number of participants in dose-expansion phase with abnormal clinical laboratory parameters reported as TEAEs are reported. Abnormal clinical laboratory parameters defined as any abnormal finding during analysis of serum chemistry, hematology, coagulation, and urine. As-treated population (participants who received any study drug [MEDI0680, durvalumab, or nivolumab] and grouped according to actual treatment received) was analysed for this end point.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 through 90 days post end of treatment (approximately 5 years 10 months)

Notes:

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 20 mg/kg	MEDI0680 20 mg/kg + Durvalumab 750 mg	Nivolumab 240 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	42	21	
Units: Participants				
Anaemia	1	6	5	
Neutropenia	0	1	0	
Blood iron decreased	0	0	1	
Lymphocyte count decreased	0	0	1	
Neutrophil count decreased	1	1	0	
Platelet count decreased	0	0	1	
Platelet count increased	0	0	1	
Prothrombin time prolonged	0	0	1	
White blood cell count increased	0	0	1	
Alanine aminotransferase increased	1	1	3	
Amylase decreased	0	0	1	
Amylase increased	1	3	3	
Aspartate aminotransferase increased	1	2	3	
Blood alkaline phosphatase increased	0	0	1	
Blood bilirubin increased	0	0	1	
Blood creatine increased	1	1	0	
Blood creatine phosphokinase increased	0	1	0	
Blood creatinine increased	1	4	3	
Blood glucose increased	0	0	1	
Blood triglycerides increased	0	1	1	
C-reactive protein increased	0	1	1	
Lipase increased	1	4	2	
Transaminases increased	0	1	0	
Hypercalcaemia	0	6	2	
Hyperglycaemia	0	1	0	
Hyperkalaemia	0	2	2	

Hypertriglyceridaemia	0	1	0	
Hypoalbuminaemia	0	2	0	
Hypocalcaemia	0	1	0	
Hypoglycaemia	0	1	0	
Hypokalaemia	0	5	2	
Hypomagnesaemia	0	4	2	
Hyponatraemia	1	3	1	
Hypophosphataemia	0	1	3	
Urine abnormality	0	1	0	
Blood thyroid stimulating hormone increased	0	2	2	
Blood urine present	0	0	1	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Abnormal Vital Signs and Physical Examinations Reported as TEAEs in Dose-expansion Phase

End point title	Number of Participants With Abnormal Vital Signs and Physical Examinations Reported as TEAEs in Dose-expansion Phase ^[31]
-----------------	--------------------------------------------------------------------------------------------------------------------------------------

End point description:

Number of participants in dose-expansion phase with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs is defined as any abnormal finding in the vital sign parameters (blood pressure, heart rate, body temperature, and respiratory rate). Abnormal physical examination findings are defined as any abnormal finding in the following body systems: head and neck, respiratory, cardiovascular, gastrointestinal, urogenital, musculoskeletal, neurological, psychiatric, dermatological, hematologic/lymphatic, and endocrine systems, and weight. As-treated population (participants who received any study drug [MEDI0680, durvalumab, or nivolumab] and grouped according to actual treatment received) was analysed for this end point.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 through 90 days post end of treatment (approximately 5 years 10 months)

Notes:

[31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 20 mg/kg	MEDI0680 20 mg/kg + Durvalumab 750 mg	Nivolumab 240 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	42	21	
Units: Participants				
Atrial fibrillation	0	2	1	
Tachycardia	0	1	0	
Pyrexia	2	9	2	
Weight decreased	0	5	0	
Weight increased	0	3	0	
Hypoxia	0	1	1	
Hypertension	1	5	0	

Hypotension	1	2	1	
-------------	---	---	---	--

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Abnormal ECGs Reported as TEAEs in Dose-expansion Phase

End point title	Number of Participants With Abnormal ECGs Reported as TEAEs in Dose-expansion Phase ^[32]
-----------------	-----------------------------------------------------------------------------------------------------

End point description:

Number of participants in dose-expansion phase with abnormal ECG parameters reported as TEAEs are reported. As-treated population (participants who received any study drug [MEDI0680, durvalumab, or nivolumab] and grouped according to actual treatment received) was analysed for this end point.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 through 90 days post end of treatment (approximately 5 years 10 months)

Notes:

[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 20 mg/kg	MEDI0680 20 mg/kg + Durvalumab 750 mg	Nivolumab 240 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	42	21	
Units: Participants				
Angina pectoris	1	1	0	
Tachycardia	0	1	0	
Atrial fibrillation	0	2	1	
Cardiac failure congestive	0	0	1	

Statistical analyses

No statistical analyses for this end point

Secondary: Serum Concentration of MEDI0680 in Dose-escalation and Dose-expansion Phases

End point title	Serum Concentration of MEDI0680 in Dose-escalation and Dose-expansion Phases ^[33]
-----------------	----------------------------------------------------------------------------------------------

End point description:

Serum concentration of MEDI0680 were assessed using parameters Cmin (pre-dose) and Cmax (end of infusion), where Cmin was trough concentration and Cmax was peak concentration. Participants from As-treated population who received MEDI0680, grouped according to actual treatment received, and had quantifiable and calculable serum samples at the specified time points were analysed for this end point.

The arbitrary number 9999.9 signified the sample was not quantifiable and therefore, not calculable. The arbitrary number 0.0009 signified no data as no participants were analysed for the specified time points. Here, 'n' denotes the number of participants analysed at the specified time points.

End point type	Secondary
End point timeframe:	
Pre-dose and end of infusion on Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1	

Notes:

[33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 0.1 mg/kg + Durvalumab 3 mg	MEDI0680 0.1 mg/kg + Durvalumab 10 mg	MEDI0680 0.5 mg/kg + Durvalumab 10 mg	MEDI0680 2.5 mg/kg + Durvalumab 10 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	5	3	3
Units: µg/mL				
geometric mean (geometric coefficient of variation)				
Cmin at Cycle1 Day1 (n = 4, 5, 3, 3, 9, 6, 4, 40)	9999.9 (± 9999.9)	9999.9 (± 9999.9)	9999.9 (± 9999.9)	9999.9 (± 9999.9)
Cmax at Cycle1 Day1 (n = 4, 5, 3, 3, 9, 4, 4, 38)	4.330 (± 26.18)	3.877 (± 54.68)	16.36 (± 26.46)	69.28 (± 24.76)
Cmin at Cycle1 Day15 (n = 4, 3, 3, 3, 8, 5, 0, 0)	1.143 (± 22.70)	0.9937 (± 35.93)	4.428 (± 62.38)	18.67 (± 12.88)
Cmax at Cycle1 Day15 (n = 4, 3, 3, 3, 8, 5, 0, 0)	5.420 (± 21.61)	3.835 (± 25.30)	20.52 (± 26.26)	87.78 (± 20.69)
Cmin at Cycle2 Day1 (n = 4, 4, 3, 3, 7, 6, 4, 36)	1.645 (± 49.08)	1.361 (± 38.07)	7.879 (± 52.74)	31.81 (± 4.480)
Cmax at Cycle2 Day1 (n = 4, 4, 3, 3, 7, 6, 4, 34)	3.515 (± 145.9)	3.688 (± 80.17)	17.28 (± 56.32)	92.07 (± 17.72)

End point values	MEDI0680 10 mg/kg + Durvalumab 10 mg	MEDI0680 20 mg/kg + Durvalumab 10 mg	MEDI0680 20 mg/kg	MEDI0680 20 mg/kg + Durvalumab 750 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	6	4	40
Units: µg/mL				
geometric mean (geometric coefficient of variation)				
Cmin at Cycle1 Day1 (n = 4, 5, 3, 3, 9, 6, 4, 40)	9999.9 (± 9999.9)	9999.9 (± 9999.9)	9999.9 (± 9999.9)	9999.9 (± 9999.9)
Cmax at Cycle1 Day1 (n = 4, 5, 3, 3, 9, 4, 4, 38)	272.4 (± 24.62)	529.9 (± 29.84)	668.8 (± 21.04)	135.9 (± 4007)
Cmin at Cycle1 Day15 (n = 4, 3, 3, 3, 8, 5, 0, 0)	46.87 (± 559.4)	205.8 (± 24.56)	0.0009 (± 0.0009)	0.0009 (± 0.0009)
Cmax at Cycle1 Day15 (n = 4, 3, 3, 3, 8, 5, 0, 0)	348.1 (± 27.78)	716.8 (± 26.72)	0.0009 (± 0.0009)	0.0009 (± 0.0009)
Cmin at Cycle2 Day1 (n = 4, 4, 3, 3, 7, 6, 4, 36)	155.7 (± 24.20)	378.0 (± 17.95)	308.6 (± 30.45)	253.9 (± 52.11)
Cmax at Cycle2 Day1 (n = 4, 4, 3, 3, 7, 6, 4, 34)	440.7 (± 28.18)	860.8 (± 13.82)	936.1 (± 24.91)	586.6 (± 63.42)

Statistical analyses

No statistical analyses for this end point

Secondary: Serum Concentration of Durvalumab in Dose-escalation and Dose-expansion Phases

End point title	Serum Concentration of Durvalumab in Dose-escalation and Dose-expansion Phases ^[34]
-----------------	------------------------------------------------------------------------------------------------

End point description:

Serum concentration of durvalumab were assessed using parameters Cmin (pre-dose) and Cmax (end of infusion), where Cmin was trough concentration and Cmax was peak concentration. Participants from As-treated population who received durvalumab, grouped according to actual treatment received, and had quantifiable and calculable serum samples at the specified time points were analysed for this end point. The arbitrary number 9999.9 signified the sample was not quantifiable and therefore, not calculable. The arbitrary number 0.0009 signified no data as no participants were analysed for the specified time points. Here, 'n' denotes the number of participants analysed at the specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose and end of infusion on Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1

Notes:

[34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDIO680 0.1 mg/kg + Durvalumab 3 mg	MEDIO680 0.1 mg/kg + Durvalumab 10 mg	MEDIO680 0.5 mg/kg + Durvalumab 10 mg	MEDIO680 2.5 mg/kg + Durvalumab 10 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	5	3	3
Units: µg/mL				
geometric mean (geometric coefficient of variation)				
Cmin at Cycle1 Day1 (n = 4, 5, 3, 3, 9, 6, 38)	9999.9 (± 9999.9)	9999.9 (± 9999.9)	9999.9 (± 9999.9)	9999.9 (± 9999.9)
Cmax at Cycle1 Day1 (n = 4, 5, 3, 3, 9, 6, 41)	65.47 (± 10.02)	216.1 (± 25.14)	213.8 (± 9.943)	188.0 (± 17.82)
Cmin at Cycle1 Day15 (n = 4, 3, 3, 3, 8, 6, 0)	19.62 (± 16.49)	63.02 (± 7.836)	49.04 (± 80.97)	86.10 (± 69.76)
Cmax at Cycle1 Day15 (n = 4, 3, 3, 3, 8, 6, 0)	95.14 (± 12.79)	245.8 (± 13.45)	241.1 (± 30.90)	225.0 (± 9.213)
Cmin at Cycle2 Day1 (n = 4, 4, 3, 3, 7, 6, 27)	23.83 (± 14.35)	83.76 (± 34.29)	89.20 (± 56.00)	136.3 (± 45.72)
Cmax at Cycle2 Day1 (n = 4, 4, 3, 3, 7, 6, 32)	84.43 (± 17.13)	280.9 (± 12.48)	297.5 (± 42.41)	267.0 (± 25.97)

End point values	MEDIO680 10	MEDIO680 20	MEDIO680 20	
------------------	-------------	-------------	-------------	--

	mg/kg + Durvalumab 10 mg	mg/kg + Durvalumab 10 mg	mg/kg + Durvalumab 750 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	6	41	
Units: µg/mL				
geometric mean (geometric coefficient of variation)				
Cmin at Cycle1 Day1 (n = 4, 5, 3, 3, 9, 6, 38)	9999.9 (± 9999.9)	9999.9 (± 9999.9)	9999.9 (± 9999.9)	
Cmax at Cycle1 Day1 (n = 4, 5, 3, 3, 9, 6, 41)	248.0 (± 27.20)	253.9 (± 11.35)	186.9 (± 33.42)	
Cmin at Cycle1 Day15 (n = 4, 3, 3, 3, 8, 6, 0)	79.59 (± 63.46)	70.31 (± 22.00)	0.0009 (± 0.0009)	
Cmax at Cycle1 Day15 (n = 4, 3, 3, 3, 8, 6, 0)	292.7 (± 33.84)	321.8 (± 23.05)	0.0009 (± 0.0009)	
Cmin at Cycle2 Day1 (n = 4, 4, 3, 3, 7, 6, 27)	124.8 (± 55.78)	142.5 (± 50.52)	78.41 (± 55.62)	
Cmax at Cycle2 Day1 (n = 4, 4, 3, 3, 7, 6, 32)	370.9 (± 42.57)	342.3 (± 18.08)	258.1 (± 28.36)	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Positive Anti-drug Antibodies (ADA) to MEDI0680 in Dose-escalation and Dose-expansion Phases

End point title	Number of Participants With Positive Anti-drug Antibodies (ADA) to MEDI0680 in Dose-escalation and Dose-expansion Phases ^[35]
-----------------	------------------------------------------------------------------------------------------------------------------------------------------

End point description:

Number of participants with positive ADAs to MEDI0680 are reported. Persistent positive is defined as positive at ≥ 2 post-baseline assessments (with ≥ 16 weeks between first and last positive) or positive at last post-baseline assessment. Transient positive is defined as negative at last post-baseline assessment and positive at only one post-baseline assessment or at ≥ 2 post-baseline assessments (with < 16 weeks between first and last positive). As-treated population (participants who received MEDI0680 and grouped according to actual treatment received) was analysed for this end point.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 1, Cycle 2 Day 1, Cycle 5 Day 1, Cycle 8 Day 1, Cycle 11 Day 1, 90 and 180 days post end of treatment (approximately 5 years and 10 months)

Notes:

[35] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 0.1 mg/kg + Durvalumab 3 mg	MEDI0680 0.1 mg/kg + Durvalumab 10 mg	MEDI0680 0.5 mg/kg + Durvalumab 10 mg	MEDI0680 2.5 mg/kg + Durvalumab 10 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	5	3	3
Units: Participants				
ADA positive post-baseline	2	0	2	0
Persistent Positive	2	0	2	0

Transient Positive	0	0	0	0
--------------------	---	---	---	---

End point values	MEDI0680 10 mg/kg + Durvalumab 10 mg	MEDI0680 20 mg/kg + Durvalumab 10 mg	MEDI0680 20 mg/kg	MEDI0680 20 mg/kg + Durvalumab 750 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	6	4	39
Units: Participants				
ADA positive post-baseline	0	0	0	2
Persistent Positive	0	0	0	0
Transient Positive	0	0	0	2

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Positive ADA to Durvalumab in Dose-escalation and Dose-expansion Phases

End point title	Number of Participants With Positive ADA to Durvalumab in Dose-escalation and Dose-expansion Phases ^[36]
-----------------	---------------------------------------------------------------------------------------------------------------------

End point description:

Number of participants with positive ADA to durvalumab are reported. Persistent positive is defined as positive at ≥ 2 post-baseline assessments (with ≥ 16 weeks between first and last positive) or positive at last post-baseline assessment. Transient positive is defined as negative at last post-baseline assessment and positive at only one post-baseline assessment or at ≥ 2 post-baseline assessments (with < 16 weeks between first and last positive). As-treated population (participants who received durvalumab and grouped according to actual treatment received) was analysed for this end point.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1 Day 1, Cycle 2 Day 1, Cycle 5 Day 1, Cycle 8 Day 1, Cycle 11 Day 1, 90 and 180 days post end of treatment (approximately 5 years and 10 months)

Notes:

[36] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 0.1 mg/kg + Durvalumab 3 mg	MEDI0680 0.1 mg/kg + Durvalumab 10 mg	MEDI0680 0.5 mg/kg + Durvalumab 10 mg	MEDI0680 2.5 mg/kg + Durvalumab 10 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	5	3	3
Units: Participants				
ADA positive post-baseline	1	0	0	0
Persistent Positive	1	0	0	0
Transient Positive	0	0	0	0

End point values	MEDI0680 10 mg/kg + Durvalumab 10 mg	MEDI0680 20 mg/kg + Durvalumab 10 mg	MEDI0680 20 mg/kg + Durvalumab 750 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	8	6	39	
Units: Participants				
ADA positive post-baseline	0	0	2	
Persistent Positive	0	0	2	
Transient Positive	0	0	0	

Statistical analyses

No statistical analyses for this end point

Secondary: ORR for Participants With Programmed Cell Death Ligand 1 (PD-L1) Status Positive and Negative in Dose-expansion Phase

End point title	ORR for Participants With Programmed Cell Death Ligand 1 (PD-L1) Status Positive and Negative in Dose-expansion Phase ^[37]
-----------------	---------------------------------------------------------------------------------------------------------------------------------------

End point description:

ORR for participants with PD-L1 status positive and negative are reported. The ORR is defined as best overall response of confirmed CR or confirmed PR based on RECIST v1.1. The CR is defined as disappearance of all target and non-target lesions and no new lesions. The PR is defined as $\geq 30\%$ decrease in the sum of diameters of target lesions (compared to baseline) and no new non-target lesion. A confirmed CR or PR is defined as 2 CRs or 2 PRs that were separated by at least 4 weeks with no evidence of progression in-between. Participants from As-treated population with PD-L1 positive ($> 1\%$ tumor cell membrane or $> 1\%$ immune cell staining) and PD-L1 negative ($\leq 1\%$ tumor cell membrane and $\leq 1\%$ immune cell staining) were analysed for this end point.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline (Day -42 to Day -1) through disease progression or end of treatment (approximately 5 years 10 months)

Notes:

[37] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only those baseline period arms for which analysis was planned were reported in the end point.

End point values	MEDI0680 20 mg/kg	MEDI0680 20 mg/kg + Durvalumab 750 mg	Nivolumab 240 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	42	21	
Units: Percentage of Participants				
number (confidence interval 95%)				
Participants with PD-L1 positive	0 (0 to 97.5)	40.0 (5.3 to 85.3)	37.5 (8.5 to 75.5)	
Participants with PD-L1 negative	0 (0 to 70.8)	13.5 (4.5 to 28.8)	15.4 (1.9 to 45.4)	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Day 1 through 90 days post end of treatment (approximately 5 years 10 months)

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22.1
--------------------	------

Reporting groups

Reporting group title	MEDI0680 0.1 mg/kg Q2W + Durva 3 mg/kg Q2W
-----------------------	--------------------------------------------

Reporting group description: -

Reporting group title	MEDI0680 0.1 mg/kg Q2W + Durva 10 mg/kg Q2W
-----------------------	---------------------------------------------

Reporting group description: -

Reporting group title	MEDI0680 0.5 mg/kg Q2W + Durva 10 mg/kg Q2W
-----------------------	---------------------------------------------

Reporting group description: -

Reporting group title	MEDI0680 2.5 mg/kg Q2W + Durva 10 mg/kg Q2W
-----------------------	---------------------------------------------

Reporting group description: -

Reporting group title	MEDI0680 10 mg/kg Q2W + Durva 10 mg/kg Q2W
-----------------------	--------------------------------------------

Reporting group description: -

Reporting group title	MEDI0680 20 mg/kg Q2W + Durva 10 mg/kg Q2W
-----------------------	--------------------------------------------

Reporting group description: -

Reporting group title	MEDI0680 20 mg/kg Q2W
-----------------------	-----------------------

Reporting group description: -

Reporting group title	MEDI0680 20 mg/kg Q2W + Durva 750 mg Q2W
-----------------------	------------------------------------------

Reporting group description: -

Reporting group title	Nivolumab 240mg Q2W
-----------------------	---------------------

Reporting group description: -

Serious adverse events	MEDI0680 0.1 mg/kg Q2W + Durva 3 mg/kg Q2W	MEDI0680 0.1 mg/kg Q2W + Durva 10 mg/kg Q2W	MEDI0680 0.5 mg/kg Q2W + Durva 10 mg/kg Q2W
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 4 (25.00%)	1 / 5 (20.00%)	1 / 3 (33.33%)
number of deaths (all causes)	2	2	1
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Metastases to bone			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to central nervous system			

subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of skin			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypotension			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral ischaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chills			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pyrexia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Mental status changes			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			

subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transaminases increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Hip fracture			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Nervous system disorders			
Aphasia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrospinal fluid leakage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis autoimmune			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial mass			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			

Eye pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis microscopic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune-mediated enterocolitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune-mediated pancreatitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			

subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatocellular injury			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Diabetic foot			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash maculo-papular			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash papular			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			

Adrenal insufficiency			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia of malignancy			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperthyroidism			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypothyroidism			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myalgia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pain in extremity			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pathological fracture			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			

subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	MEDI0680 2.5 mg/kg Q2W + Durva 10 mg/kg Q2W	MEDI0680 10 mg/kg Q2W + Durva 10 mg/kg Q2W	MEDI0680 20 mg/kg Q2W + Durva 10 mg/kg Q2W
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 3 (66.67%)	6 / 9 (66.67%)	0 / 6 (0.00%)
number of deaths (all causes)	2	5	1
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Metastases to bone			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to central nervous system			

subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of skin			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypotension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral ischaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chills			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 3 (0.00%)	2 / 9 (22.22%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Mental status changes			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			

subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transaminases increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Hip fracture			
subjects affected / exposed	1 / 3 (33.33%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Nervous system disorders			
Aphasia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrospinal fluid leakage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis autoimmune			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	1 / 3 (33.33%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial mass			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			

Eye pain			
subjects affected / exposed	1 / 3 (33.33%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis microscopic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune-mediated enterocolitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune-mediated pancreatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			

subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatocellular injury			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Diabetic foot			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash maculo-papular			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash papular			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			

Adrenal insufficiency			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia of malignancy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperthyroidism			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypothyroidism			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myalgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pain in extremity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pathological fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			

subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	MEDI0680 20 mg/kg Q2W	MEDI0680 20 mg/kg Q2W + Durva 750 mg Q2W	Nivolumab 240mg Q2W
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 4 (75.00%)	22 / 42 (52.38%)	13 / 21 (61.90%)
number of deaths (all causes)	2	9	4
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Metastases to bone			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to central nervous system			

subjects affected / exposed	1 / 4 (25.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of skin			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypotension			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral ischaemia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chills			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	1 / 21 (4.76%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pyrexia			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	4 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	1 / 21 (4.76%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Mental status changes			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			

subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transaminases increased			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Hip fracture			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Nervous system disorders			
Aphasia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	1 / 21 (4.76%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrospinal fluid leakage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis autoimmune			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial mass			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	1 / 4 (25.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			

Eye pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 4 (25.00%)	0 / 42 (0.00%)	2 / 21 (9.52%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis microscopic			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune-mediated enterocolitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune-mediated pancreatitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			

subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	1 / 4 (25.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatocellular injury			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Diabetic foot			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash maculo-papular			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash papular			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			

Adrenal insufficiency			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia of malignancy			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperthyroidism			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypothyroidism			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	3 / 21 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myalgia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pain in extremity			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pathological fracture			
subjects affected / exposed	1 / 4 (25.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal pain			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord infection			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			

subjects affected / exposed	1 / 4 (25.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	MEDI0680 0.1 mg/kg Q2W + Durva 3 mg/kg Q2W	MEDI0680 0.1 mg/kg Q2W + Durva 10 mg/kg Q2W	MEDI0680 0.5 mg/kg Q2W + Durva 10 mg/kg Q2W
Total subjects affected by non-serious adverse events			
subjects affected / exposed	4 / 4 (100.00%)	5 / 5 (100.00%)	3 / 3 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oesophageal adenocarcinoma			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Seborrhoeic keratosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Squamous cell carcinoma			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tumour pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Aortic aneurysm			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Aortic occlusion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Deep vein thrombosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Embolism			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Flushing			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Hot flush			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Hypotension			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vena cava embolism			

subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Axillary pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Catheter site pruritus			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cyst			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Facial pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Fatigue			
subjects affected / exposed	1 / 4 (25.00%)	3 / 5 (60.00%)	1 / 3 (33.33%)
occurrences (all)	2	3	1
Feeling hot			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Gait disturbance			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Inflammation			

subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Infusion site pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Mass			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Mucosal inflammation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nodule			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Oedema			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)
occurrences (all)	2	0	1
Pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	2 / 3 (66.67%)
occurrences (all)	0	0	2
Secretion discharge			

subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Temperature intolerance subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Immune system disorders Allergy to arthropod sting subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Contrast media reaction subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Reproductive system and breast disorders Breast mass subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Erectile dysfunction subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Galactorrhoea subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Pruritus genital subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Cough subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 5 (20.00%) 1	1 / 3 (33.33%) 1
Dry throat subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0

Dysphonia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	1 / 4 (25.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Dyspnoea exertional			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Epistaxis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Haemoptysis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hiccups			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypoxia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Laryngeal obstruction			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Lung disorder			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Oropharyngeal discomfort			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Painful respiration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Paranasal sinus hypersecretion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pleural effusion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pneumonitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pulmonary haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rales			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rhinitis allergic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sinus congestion			
subjects affected / exposed	1 / 4 (25.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences (all)	2	1	0
Sneezing			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Wheezing subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Psychiatric disorders			
Agitation subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Anxiety subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	1 / 5 (20.00%) 1	0 / 3 (0.00%) 0
Confusional state subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Delirium subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Depression subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Insomnia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Mood altered subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Investigations			
Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Amylase decreased subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Amylase increased			

subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)
occurrences (all)	3	0	1
Blood bilirubin increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood creatine increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood fibrinogen decreased			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Blood glucose increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood iron decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood phosphorus decreased			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Blood testosterone decreased			

subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood thyroid stimulating hormone increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood triglycerides increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood urea increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood urine present			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
C-reactive protein increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
General physical condition abnormal			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
International normalised ratio increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lipase increased			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)
occurrences (all)	2	0	3
Lymphocyte count decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			

subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Platelet count increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Procalcitonin increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Prothrombin time prolonged			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Serum ferritin decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tri-iodothyronine free abnormal			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Weight increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
White blood cell count increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eastern Cooperative Oncology Group performance status worsened			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Electrocardiogram QT prolonged subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Electrocardiogram T wave abnormal subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Influenza B virus test positive subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Injury, poisoning and procedural complications			
Anaemia postoperative subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Arthropod bite subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Chemical burn of skin subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Contusion subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Cystitis radiation subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Fall subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 5 (20.00%) 1	0 / 3 (0.00%) 0
Humerus fracture subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Infusion related reaction subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Post procedural oedema			

subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Radiation skin injury			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Rib fracture			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Scratch			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Skin abrasion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Spinal compression fracture			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sunburn			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Wound			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Atrial fibrillation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cardiac failure congestive			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Palpitations			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Sinus tachycardia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Facial paralysis			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Head discomfort			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperaesthesia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypoaesthesia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Hyposmia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lethargy			

subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Memory impairment			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neuralgia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sensory disturbance			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	2 / 4 (50.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	2
Iron deficiency anaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Leukocytosis			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Lymphopenia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Ear discomfort			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	1 / 3 (33.33%)
occurrences (all)	0	1	1
Ear disorder			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ear pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypoacusis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tinnitus			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Asthenopia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Conjunctival haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis allergic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Diplopia			

subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Episcleritis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eye irritation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eye pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eye pruritus			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eyelid ptosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Keratitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lacrimation increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ocular hyperaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Periorbital swelling			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Photophobia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vision blurred			

subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Visual impairment			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Abdominal distension			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Abdominal mass			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	1 / 4 (25.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences (all)	2	2	0
Abdominal pain lower			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Abdominal pain upper			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Aphthous ulcer			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Ascites			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Colitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	1 / 4 (25.00%)	2 / 5 (40.00%)	0 / 3 (0.00%)
occurrences (all)	1	2	0

Diarrhoea			
subjects affected / exposed	1 / 4 (25.00%)	2 / 5 (40.00%)	0 / 3 (0.00%)
occurrences (all)	3	3	0
Dry mouth			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Duodenitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Dysphagia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Epigastric discomfort			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Faeces soft			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	1 / 4 (25.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences (all)	2	1	0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gingival pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Haemorrhoids			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Immune-mediated enterocolitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Inguinal hernia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	1 / 4 (25.00%)	1 / 5 (20.00%)	1 / 3 (33.33%)
occurrences (all)	3	1	1
Odynophagia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oral disorder			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oral pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pancreatitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Hepatobiliary disorders			
Cholelithiasis			

subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hepatocellular injury			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hepatotoxicity			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Liver disorder			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Dermatitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dermatitis acneiform			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Diabetic foot			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ecchymosis			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Erythema			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0

Macule			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pain of skin			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Papule			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Perioral dermatitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	2
Rash			
subjects affected / exposed	2 / 4 (50.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences (all)	2	1	0
Rash maculo-papular			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Scar pain			

subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin discolouration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin fissures			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin lesion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin ulcer			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vitiligo			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Xeroderma			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Micturition urgency			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Nocturia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0

Proteinuria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Renal tubular necrosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urinary incontinence			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urinary retention			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urinary tract pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urine abnormality			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypercalcaemia of malignancy			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperthyroidism			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Hypothyroidism			
subjects affected / exposed	0 / 4 (0.00%)	2 / 5 (40.00%)	0 / 3 (0.00%)
occurrences (all)	0	3	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Arthritis			

subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	1 / 4 (25.00%)	2 / 5 (40.00%)	0 / 3 (0.00%)
occurrences (all)	1	2	0
Bone lesion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Flank pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Groin pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Joint range of motion decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Joint swelling			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Limb discomfort			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Muscle spasms			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	3	0	0
Musculoskeletal stiffness			

subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	2 / 4 (50.00%) 2	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Neck pain subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Osteoarthritis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Pain in extremity subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 5 (20.00%) 1	0 / 3 (0.00%) 0
Pain in jaw subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Pathological fracture subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Spinal pain subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Tendon disorder subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Infections and infestations Abscess subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Bronchiolitis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0
Bronchitis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 5 (0.00%) 0	0 / 3 (0.00%) 0

Conjunctivitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ear infection			
subjects affected / exposed	2 / 4 (50.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	3	0	0
Eye infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal fungal infection			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Gingivitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Herpes zoster			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hordeolum			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Kidney infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection bacterial			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			

subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oral candidiasis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Oral fungal infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Otitis media			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Rash pustular			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tooth abscess			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tooth infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			

subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Viral infection			
subjects affected / exposed	0 / 4 (0.00%)	1 / 5 (20.00%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Acidosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Decreased appetite			
subjects affected / exposed	1 / 4 (25.00%)	1 / 5 (20.00%)	2 / 3 (66.67%)
occurrences (all)	2	1	2
Dehydration			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Glucose tolerance impaired			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gout			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypercalcaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperkalaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Hypermagnesaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Hypertriglyceridaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperuricaemia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Hypoalbuminaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypocalcaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypoglycaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypomagnesaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyponatraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypophosphataemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Metabolic alkalosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 4 (0.00%)	0 / 5 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	MEDI0680 2.5 mg/kg Q2W + Durva 10 mg/kg Q2W	MEDI0680 10 mg/kg Q2W + Durva 10 mg/kg Q2W	MEDI0680 20 mg/kg Q2W + Durva 10 mg/kg Q2W
Total subjects affected by non-serious adverse events subjects affected / exposed	3 / 3 (100.00%)	9 / 9 (100.00%)	6 / 6 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Oesophageal adenocarcinoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Seborrhoeic keratosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Squamous cell carcinoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Tumour pain			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Vascular disorders			
Aortic aneurysm			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Aortic occlusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Deep vein thrombosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Embolism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Flushing			

subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	1 / 6 (16.67%)
occurrences (all)	0	1	1
Hot flush			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	1 / 6 (16.67%)
occurrences (all)	0	1	3
Hypotension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vena cava embolism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Axillary pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Catheter site pruritus			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Cyst			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Facial pain			

subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	1 / 3 (33.33%)	2 / 9 (22.22%)	2 / 6 (33.33%)
occurrences (all)	1	2	3
Feeling hot			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gait disturbance			
subjects affected / exposed	1 / 3 (33.33%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Inflammation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	2
Infusion site pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Mass			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Mucosal inflammation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	3
Nodule			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Oedema			

subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Oedema peripheral subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	3 / 9 (33.33%) 5	0 / 6 (0.00%) 0
Pain subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	3 / 9 (33.33%) 3	1 / 6 (16.67%) 1
Secretion discharge subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Temperature intolerance subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 9 (11.11%) 1	0 / 6 (0.00%) 0
Immune system disorders Allergy to arthropod sting subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Contrast media reaction subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Reproductive system and breast disorders Breast mass subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 9 (11.11%) 1	0 / 6 (0.00%) 0
Erectile dysfunction subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Galactorrhoea subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 9 (11.11%) 1	0 / 6 (0.00%) 0
Pruritus genital			

subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	3 / 6 (50.00%)
occurrences (all)	0	1	4
Dry throat			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dysphonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	0 / 3 (0.00%)	2 / 9 (22.22%)	0 / 6 (0.00%)
occurrences (all)	0	3	0
Dyspnoea exertional			
subjects affected / exposed	1 / 3 (33.33%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Epistaxis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Haemoptysis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hiccups			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Hypoxia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Laryngeal obstruction			

subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lung disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	1 / 6 (16.67%)
occurrences (all)	0	1	1
Oropharyngeal discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
Painful respiration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Paranasal sinus hypersecretion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pleural effusion			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Pneumonitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	1 / 3 (33.33%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	2	1	0
Pulmonary haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rales			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rhinitis allergic			

subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	1 / 6 (16.67%)
occurrences (all)	0	1	2
Sinus congestion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Sneezing			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Wheezing			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Confusional state			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Delirium			
subjects affected / exposed	1 / 3 (33.33%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Depression			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Insomnia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0

Mood altered subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 9 (11.11%) 1	0 / 6 (0.00%) 0
Investigations			
Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	1 / 6 (16.67%) 1
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 9 (11.11%) 5	0 / 6 (0.00%) 0
Amylase decreased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Amylase increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 9 (11.11%) 1	1 / 6 (16.67%) 1
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	2 / 9 (22.22%) 4	0 / 6 (0.00%) 0
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 9 (11.11%) 1	0 / 6 (0.00%) 0
Blood bilirubin increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Blood creatine increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Blood creatinine increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	2 / 9 (22.22%) 3	1 / 6 (16.67%) 1
Blood fibrinogen decreased			

subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Blood glucose increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood iron decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood phosphorus decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood testosterone decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood thyroid stimulating hormone increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood triglycerides increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood urea increased			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Blood urine present			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
C-reactive protein increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
General physical condition abnormal			

subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
International normalised ratio increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Lipase increased			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	5	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Neutrophil count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Platelet count increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Procalcitonin increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Prothrombin time prolonged			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Serum ferritin decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Tri-iodothyronine free abnormal			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	1 / 6 (16.67%)
occurrences (all)	0	1	1

Weight increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
White blood cell count decreased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	1 / 6 (16.67%) 2
White blood cell count increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Eastern Cooperative Oncology Group performance status worsened subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Electrocardiogram QT prolonged subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Electrocardiogram T wave abnormal subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Influenza B virus test positive subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Injury, poisoning and procedural complications			
Anaemia postoperative subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Arthropod bite subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Chemical burn of skin subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Contusion subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	2 / 6 (33.33%) 3
Cystitis radiation			

subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	1 / 3 (33.33%)	1 / 9 (11.11%)	2 / 6 (33.33%)
occurrences (all)	2	1	2
Humerus fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Infusion related reaction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Post procedural oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Radiation skin injury			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rib fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Scratch			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin abrasion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Spinal compression fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Sunburn			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Wound			

subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Atrial fibrillation			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Cardiac failure congestive			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Sinus tachycardia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Tachycardia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	2 / 6 (33.33%)
occurrences (all)	0	1	3
Dysgeusia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Facial paralysis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Head discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Headache			

subjects affected / exposed	1 / 3 (33.33%)	2 / 9 (22.22%)	0 / 6 (0.00%)
occurrences (all)	4	3	0
Hyperaesthesia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Hypoaesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hyposmia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Lethargy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Memory impairment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Neuralgia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Neuropathy peripheral			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Paraesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Sciatica			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Sensory disturbance			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Somnolence			

subjects affected / exposed	1 / 3 (33.33%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Tremor			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 3 (33.33%)	3 / 9 (33.33%)	0 / 6 (0.00%)
occurrences (all)	1	5	0
Iron deficiency anaemia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Leukocytosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
Neutropenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Ear discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ear disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ear pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Hypoacusis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Tinnitus			

subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Eye disorders			
Asthenopia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Conjunctival haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis allergic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Diplopia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Episcleritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eye irritation			
subjects affected / exposed	0 / 3 (0.00%)	2 / 9 (22.22%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
Eye pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eye pruritus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eyelid ptosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Keratitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Lacrimation increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	2
Ocular hyperaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Periorbital swelling			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Photophobia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Visual impairment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Abdominal mass			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Abdominal pain lower			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			

subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Aphthous ulcer			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ascites			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Colitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	1 / 3 (33.33%)	0 / 9 (0.00%)	2 / 6 (33.33%)
occurrences (all)	1	0	2
Diarrhoea			
subjects affected / exposed	0 / 3 (0.00%)	3 / 9 (33.33%)	5 / 6 (83.33%)
occurrences (all)	0	12	5
Dry mouth			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Duodenitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dysphagia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Epigastric discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Faeces soft			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Flatulence			

subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gingival pain			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Haemorrhoids			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Immune-mediated enterocolitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Inguinal hernia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Nausea			
subjects affected / exposed	2 / 3 (66.67%)	5 / 9 (55.56%)	1 / 6 (16.67%)
occurrences (all)	3	7	3
Odynophagia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Oral disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Oral pain			
subjects affected / exposed	0 / 3 (0.00%)	2 / 9 (22.22%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
Pancreatitis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	1 / 3 (33.33%)	2 / 9 (22.22%)	2 / 6 (33.33%)
occurrences (all)	1	2	2
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hepatocellular injury			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hepatotoxicity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Liver disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dermatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dermatitis acneiform			

subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Diabetic foot			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Ecchymosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Macule			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Pain of skin			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Palmar-plantar erythrodysesthesia syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Papule			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Perioral dermatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	1 / 3 (33.33%)	5 / 9 (55.56%)	0 / 6 (0.00%)
occurrences (all)	1	10	0

Rash			
subjects affected / exposed	1 / 3 (33.33%)	4 / 9 (44.44%)	2 / 6 (33.33%)
occurrences (all)	1	4	2
Rash maculo-papular			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Scar pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin discolouration			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Skin fissures			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin lesion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Skin ulcer			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Vitiligo			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Xeroderma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1

Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Micturition urgency			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nocturia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Proteinuria			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Renal tubular necrosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Urinary incontinence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Urinary retention			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Urinary tract pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Urine abnormality			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypercalcaemia of malignancy			

subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hyperthyroidism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypothyroidism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 3 (33.33%)	2 / 9 (22.22%)	2 / 6 (33.33%)
occurrences (all)	1	2	2
Arthritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	2 / 6 (33.33%)
occurrences (all)	0	0	2
Back pain			
subjects affected / exposed	0 / 3 (0.00%)	2 / 9 (22.22%)	1 / 6 (16.67%)
occurrences (all)	0	2	1
Bone lesion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Flank pain			
subjects affected / exposed	1 / 3 (33.33%)	2 / 9 (22.22%)	1 / 6 (16.67%)
occurrences (all)	1	2	1
Groin pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Joint range of motion decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Joint swelling			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Limb discomfort			

subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	2 / 6 (33.33%)
occurrences (all)	0	1	4
Muscular weakness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	1 / 3 (33.33%)	0 / 9 (0.00%)	2 / 6 (33.33%)
occurrences (all)	1	0	2
Musculoskeletal stiffness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
Neck pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Osteoarthritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	2 / 6 (33.33%)
occurrences (all)	0	0	2
Pain in jaw			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pathological fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Spinal pain			

subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Tendon disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Abscess			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Bronchiolitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Ear infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eye infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal fungal infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gingivitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Herpes zoster			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Hordeolum			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Influenza			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Kidney infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection bacterial			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Oral candidiasis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Oral fungal infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Otitis media			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rash pustular			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			

subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Tooth abscess			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Tooth infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	1 / 3 (33.33%)	2 / 9 (22.22%)	3 / 6 (50.00%)
occurrences (all)	1	3	4
Urinary tract infection			
subjects affected / exposed	1 / 3 (33.33%)	1 / 9 (11.11%)	0 / 6 (0.00%)
occurrences (all)	2	1	0
Viral infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Metabolism and nutrition disorders			
Acidosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Decreased appetite			
subjects affected / exposed	0 / 3 (0.00%)	2 / 9 (22.22%)	2 / 6 (33.33%)
occurrences (all)	0	2	4
Dehydration			
subjects affected / exposed	0 / 3 (0.00%)	1 / 9 (11.11%)	1 / 6 (16.67%)
occurrences (all)	0	1	1

Glucose tolerance impaired subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Gout subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Hypercalcaemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 9 (11.11%) 1	1 / 6 (16.67%) 1
Hyperglycaemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 9 (11.11%) 1	0 / 6 (0.00%) 0
Hyperkalaemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 9 (11.11%) 3	0 / 6 (0.00%) 0
Hypermagnesaemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Hypertriglyceridaemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Hyperuricaemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 9 (11.11%) 1	0 / 6 (0.00%) 0
Hypoalbuminaemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 9 (11.11%) 1	0 / 6 (0.00%) 0
Hypocalcaemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Hypoglycaemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 9 (0.00%) 0	0 / 6 (0.00%) 0
Hypokalaemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	2 / 9 (22.22%) 4	0 / 6 (0.00%) 0

Hypomagnesaemia			
subjects affected / exposed	0 / 3 (0.00%)	2 / 9 (22.22%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
Hyponatraemia			
subjects affected / exposed	0 / 3 (0.00%)	2 / 9 (22.22%)	1 / 6 (16.67%)
occurrences (all)	0	3	1
Hypophosphataemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Metabolic alkalosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 9 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	MEDI0680 20 mg/kg Q2W	MEDI0680 20 mg/kg Q2W + Durva 750 mg Q2W	Nivolumab 240mg Q2W
Total subjects affected by non-serious adverse events			
subjects affected / exposed	4 / 4 (100.00%)	41 / 42 (97.62%)	20 / 21 (95.24%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Oesophageal adenocarcinoma			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Seborrhoeic keratosis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Squamous cell carcinoma			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Tumour pain			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	0 / 21 (0.00%)
occurrences (all)	0	2	0
Vascular disorders			

Aortic aneurysm			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Aortic occlusion			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Deep vein thrombosis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	1 / 21 (4.76%)
occurrences (all)	0	1	1
Embolism			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Flushing			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Hot flush			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	1 / 21 (4.76%)
occurrences (all)	0	1	1
Hypertension			
subjects affected / exposed	1 / 4 (25.00%)	5 / 42 (11.90%)	0 / 21 (0.00%)
occurrences (all)	1	7	0
Hypotension			
subjects affected / exposed	1 / 4 (25.00%)	2 / 42 (4.76%)	1 / 21 (4.76%)
occurrences (all)	1	2	1
Vena cava embolism			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 4 (25.00%)	5 / 42 (11.90%)	1 / 21 (4.76%)
occurrences (all)	1	7	1
Axillary pain			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Catheter site pruritus			

subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	1 / 4 (25.00%)	2 / 42 (4.76%)	0 / 21 (0.00%)
occurrences (all)	1	2	0
Chills			
subjects affected / exposed	0 / 4 (0.00%)	3 / 42 (7.14%)	2 / 21 (9.52%)
occurrences (all)	0	3	2
Cyst			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Facial pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	4 / 4 (100.00%)	19 / 42 (45.24%)	6 / 21 (28.57%)
occurrences (all)	4	25	7
Feeling hot			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Gait disturbance			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	2 / 21 (9.52%)
occurrences (all)	0	0	2
Inflammation			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Influenza like illness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Infusion site pain			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Malaise			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Mass			

subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Mucosal inflammation			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	1 / 21 (4.76%)
occurrences (all)	0	2	1
Nodule			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	1 / 4 (25.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	1	1	0
Oedema			
subjects affected / exposed	1 / 4 (25.00%)	1 / 42 (2.38%)	2 / 21 (9.52%)
occurrences (all)	1	1	2
Oedema peripheral			
subjects affected / exposed	1 / 4 (25.00%)	5 / 42 (11.90%)	3 / 21 (14.29%)
occurrences (all)	1	7	4
Pain			
subjects affected / exposed	0 / 4 (0.00%)	3 / 42 (7.14%)	0 / 21 (0.00%)
occurrences (all)	0	3	0
Pyrexia			
subjects affected / exposed	2 / 4 (50.00%)	8 / 42 (19.05%)	2 / 21 (9.52%)
occurrences (all)	2	12	3
Secretion discharge			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Temperature intolerance			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Allergy to arthropod sting			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	2	0
Contrast media reaction			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0

Reproductive system and breast disorders			
Breast mass			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Erectile dysfunction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Galactorrhoea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Pruritus genital			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	5	0
Cough			
subjects affected / exposed	1 / 4 (25.00%)	9 / 42 (21.43%)	8 / 21 (38.10%)
occurrences (all)	2	17	9
Dry throat			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Dysphonia			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	1 / 21 (4.76%)
occurrences (all)	0	2	1
Dyspnoea			
subjects affected / exposed	0 / 4 (0.00%)	7 / 42 (16.67%)	8 / 21 (38.10%)
occurrences (all)	0	9	10
Dyspnoea exertional			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	1 / 21 (4.76%)
occurrences (all)	0	1	1
Epistaxis			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	2 / 21 (9.52%)
occurrences (all)	0	3	3

Haemoptysis			
subjects affected / exposed	1 / 4 (25.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	2	1	0
Hiccups			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Hypoxia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	1 / 21 (4.76%)
occurrences (all)	0	1	1
Laryngeal obstruction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Lung disorder			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	0 / 21 (0.00%)
occurrences (all)	0	2	0
Nasal congestion			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	2 / 21 (9.52%)
occurrences (all)	0	3	2
Oropharyngeal discomfort			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Oropharyngeal pain			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	2 / 21 (9.52%)
occurrences (all)	0	2	2
Painful respiration			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	0 / 21 (0.00%)
occurrences (all)	0	2	0
Paranasal sinus hypersecretion			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Pleural effusion			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	1 / 21 (4.76%)
occurrences (all)	0	2	1
Pneumonitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	1 / 21 (4.76%)
occurrences (all)	0	2	3

Productive cough subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	7 / 42 (16.67%) 8	2 / 21 (9.52%) 2
Pulmonary haemorrhage subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 42 (0.00%) 0	1 / 21 (4.76%) 1
Rales subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 42 (2.38%) 1	0 / 21 (0.00%) 0
Rhinitis allergic subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	2 / 42 (4.76%) 2	0 / 21 (0.00%) 0
Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	4 / 42 (9.52%) 7	2 / 21 (9.52%) 4
Sinus congestion subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 42 (2.38%) 1	0 / 21 (0.00%) 0
Sneezing subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	2 / 42 (4.76%) 2	0 / 21 (0.00%) 0
Upper-airway cough syndrome subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 42 (2.38%) 1	0 / 21 (0.00%) 0
Wheezing subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 42 (2.38%) 1	0 / 21 (0.00%) 0
Psychiatric disorders			
Agitation subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 42 (2.38%) 1	0 / 21 (0.00%) 0
Anxiety subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	2 / 42 (4.76%) 2	2 / 21 (9.52%) 2
Confusional state			

subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Delirium			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	2 / 21 (9.52%)
occurrences (all)	0	0	2
Insomnia			
subjects affected / exposed	0 / 4 (0.00%)	5 / 42 (11.90%)	3 / 21 (14.29%)
occurrences (all)	0	5	3
Mood altered			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Alanine aminotransferase increased			
subjects affected / exposed	1 / 4 (25.00%)	1 / 42 (2.38%)	3 / 21 (14.29%)
occurrences (all)	1	3	3
Amylase decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Amylase increased			
subjects affected / exposed	1 / 4 (25.00%)	3 / 42 (7.14%)	3 / 21 (14.29%)
occurrences (all)	1	6	8
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 4 (25.00%)	2 / 42 (4.76%)	3 / 21 (14.29%)
occurrences (all)	1	14	3
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Blood bilirubin increased			

subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Blood creatine increased			
subjects affected / exposed	1 / 4 (25.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	1	1	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Blood creatinine increased			
subjects affected / exposed	1 / 4 (25.00%)	4 / 42 (9.52%)	3 / 21 (14.29%)
occurrences (all)	1	5	6
Blood fibrinogen decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Blood glucose increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Blood iron decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Blood phosphorus decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Blood testosterone decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Blood thyroid stimulating hormone increased			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	2 / 21 (9.52%)
occurrences (all)	0	2	2
Blood triglycerides increased			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	1 / 21 (4.76%)
occurrences (all)	0	2	3
Blood urea increased			

subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Blood urine present			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
C-reactive protein increased			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	1 / 21 (4.76%)
occurrences (all)	0	2	1
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
General physical condition abnormal			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	0 / 21 (0.00%)
occurrences (all)	0	2	0
International normalised ratio increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Lipase increased			
subjects affected / exposed	1 / 4 (25.00%)	4 / 42 (9.52%)	2 / 21 (9.52%)
occurrences (all)	2	19	12
Lymphocyte count decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Neutrophil count decreased			
subjects affected / exposed	1 / 4 (25.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	1	3	0
Platelet count decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	2
Platelet count increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Procalcitonin increased			

subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Prothrombin time prolonged			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Serum ferritin decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Tri-iodothyronine free abnormal			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Weight decreased			
subjects affected / exposed	0 / 4 (0.00%)	5 / 42 (11.90%)	0 / 21 (0.00%)
occurrences (all)	0	7	0
Weight increased			
subjects affected / exposed	0 / 4 (0.00%)	3 / 42 (7.14%)	0 / 21 (0.00%)
occurrences (all)	0	3	0
White blood cell count decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
White blood cell count increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Eastern Cooperative Oncology Group performance status worsened			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Electrocardiogram QT prolonged			
subjects affected / exposed	1 / 4 (25.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	1	1	0
Electrocardiogram T wave abnormal			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Influenza B virus test positive			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0

Injury, poisoning and procedural complications			
Anaemia postoperative			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Arthropod bite			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	1 / 21 (4.76%)
occurrences (all)	0	1	1
Chemical burn of skin			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Contusion			
subjects affected / exposed	1 / 4 (25.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Cystitis radiation			
subjects affected / exposed	1 / 4 (25.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	2	0	0
Fall			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	0 / 21 (0.00%)
occurrences (all)	0	2	0
Humerus fracture			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Infusion related reaction			
subjects affected / exposed	0 / 4 (0.00%)	4 / 42 (9.52%)	1 / 21 (4.76%)
occurrences (all)	0	4	1
Post procedural oedema			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Procedural pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Radiation skin injury			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Rib fracture			

subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Scratch			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Skin abrasion			
subjects affected / exposed	0 / 4 (0.00%)	3 / 42 (7.14%)	1 / 21 (4.76%)
occurrences (all)	0	4	1
Spinal compression fracture			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Sunburn			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Wound			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	1 / 4 (25.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	1	1	0
Atrial fibrillation			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	1 / 21 (4.76%)
occurrences (all)	0	1	1
Cardiac failure congestive			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Palpitations			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Sinus tachycardia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0

Nervous system disorders			
Dizziness			
subjects affected / exposed	1 / 4 (25.00%)	3 / 42 (7.14%)	4 / 21 (19.05%)
occurrences (all)	3	3	4
Dysgeusia			
subjects affected / exposed	1 / 4 (25.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	1	1	0
Facial paralysis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Head discomfort			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	1 / 21 (4.76%)
occurrences (all)	0	1	1
Headache			
subjects affected / exposed	1 / 4 (25.00%)	6 / 42 (14.29%)	5 / 21 (23.81%)
occurrences (all)	2	7	7
Hyperaesthesia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Hypoaesthesia			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	1 / 21 (4.76%)
occurrences (all)	0	2	1
Hyposmia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Lethargy			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	1 / 21 (4.76%)
occurrences (all)	0	2	1
Memory impairment			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	1 / 21 (4.76%)
occurrences (all)	0	1	1
Neuralgia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Neuropathy peripheral			

subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 4 (0.00%)	5 / 42 (11.90%)	1 / 21 (4.76%)
occurrences (all)	0	6	3
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	2
Sciatica			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Sensory disturbance			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Somnolence			
subjects affected / exposed	0 / 4 (0.00%)	3 / 42 (7.14%)	0 / 21 (0.00%)
occurrences (all)	0	3	0
Tremor			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	2	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 4 (25.00%)	6 / 42 (14.29%)	5 / 21 (23.81%)
occurrences (all)	2	10	29
Iron deficiency anaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Leukocytosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0

Ear and labyrinth disorders			
Ear discomfort			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Ear disorder			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Ear pain			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Hypoacusis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Tinnitus			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Eye disorders			
Asthenopia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Conjunctival haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Conjunctivitis allergic			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Diplopia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Dry eye			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Episcleritis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Eye irritation			

subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	0 / 21 (0.00%)
occurrences (all)	0	2	0
Eye pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Eye pruritus			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	0 / 21 (0.00%)
occurrences (all)	0	2	0
Eyelid ptosis			
subjects affected / exposed	1 / 4 (25.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Keratitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Lacrimation increased			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	1 / 21 (4.76%)
occurrences (all)	0	2	1
Ocular hyperaemia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	1 / 21 (4.76%)
occurrences (all)	0	1	1
Periorbital swelling			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Photophobia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	1	0	2
Vision blurred			
subjects affected / exposed	1 / 4 (25.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Visual impairment			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0

Abdominal distension			
subjects affected / exposed	0 / 4 (0.00%)	3 / 42 (7.14%)	0 / 21 (0.00%)
occurrences (all)	0	4	0
Abdominal mass			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Abdominal pain			
subjects affected / exposed	0 / 4 (0.00%)	4 / 42 (9.52%)	3 / 21 (14.29%)
occurrences (all)	0	5	4
Abdominal pain lower			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	2
Abdominal pain upper			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	1 / 21 (4.76%)
occurrences (all)	0	2	1
Aphthous ulcer			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Ascites			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	3
Colitis			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	0 / 21 (0.00%)
occurrences (all)	0	3	0
Constipation			
subjects affected / exposed	0 / 4 (0.00%)	12 / 42 (28.57%)	6 / 21 (28.57%)
occurrences (all)	0	16	7
Diarrhoea			
subjects affected / exposed	0 / 4 (0.00%)	15 / 42 (35.71%)	9 / 21 (42.86%)
occurrences (all)	0	23	14
Dry mouth			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	3 / 21 (14.29%)
occurrences (all)	0	4	3
Duodenitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0

Dyspepsia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	3 / 21 (14.29%)
occurrences (all)	0	1	5
Dysphagia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Epigastric discomfort			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Faeces soft			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	3	0
Flatulence			
subjects affected / exposed	0 / 4 (0.00%)	3 / 42 (7.14%)	0 / 21 (0.00%)
occurrences (all)	0	3	0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Gingival bleeding			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	2 / 21 (9.52%)
occurrences (all)	0	1	2
Gingival pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	1 / 21 (4.76%)
occurrences (all)	0	1	1
Immune-mediated enterocolitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Inguinal hernia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0

Nausea			
subjects affected / exposed	3 / 4 (75.00%)	10 / 42 (23.81%)	7 / 21 (33.33%)
occurrences (all)	4	13	8
Odynophagia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Oral disorder			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	0 / 21 (0.00%)
occurrences (all)	0	2	0
Oral pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Pancreatitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Rectal haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	3 / 42 (7.14%)	0 / 21 (0.00%)
occurrences (all)	0	4	0
Stomatitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	2 / 21 (9.52%)
occurrences (all)	0	0	2
Vomiting			
subjects affected / exposed	1 / 4 (25.00%)	11 / 42 (26.19%)	6 / 21 (28.57%)
occurrences (all)	1	15	8
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	1 / 4 (25.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Hepatocellular injury			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Hepatotoxicity			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Liver disorder			

subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Alopecia			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	0 / 21 (0.00%)
occurrences (all)	0	2	0
Dermatitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Dermatitis acneiform			
subjects affected / exposed	1 / 4 (25.00%)	0 / 42 (0.00%)	2 / 21 (9.52%)
occurrences (all)	1	0	2
Diabetic foot			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	4	0
Dry skin			
subjects affected / exposed	0 / 4 (0.00%)	5 / 42 (11.90%)	4 / 21 (19.05%)
occurrences (all)	0	5	4
Ecchymosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	4
Macule			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Night sweats			
subjects affected / exposed	1 / 4 (25.00%)	3 / 42 (7.14%)	0 / 21 (0.00%)
occurrences (all)	1	3	0
Pain of skin			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1

Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Papule			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	0 / 21 (0.00%)
occurrences (all)	0	2	0
Perioral dermatitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Pruritus			
subjects affected / exposed	0 / 4 (0.00%)	7 / 42 (16.67%)	3 / 21 (14.29%)
occurrences (all)	0	10	4
Rash			
subjects affected / exposed	0 / 4 (0.00%)	7 / 42 (16.67%)	4 / 21 (19.05%)
occurrences (all)	0	9	4
Rash maculo-papular			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	4 / 21 (19.05%)
occurrences (all)	0	5	5
Rash papular			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Rash pruritic			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	1 / 21 (4.76%)
occurrences (all)	0	1	1
Scar pain			
subjects affected / exposed	1 / 4 (25.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Skin discolouration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Skin fissures			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Skin lesion			

subjects affected / exposed	1 / 4 (25.00%)	1 / 42 (2.38%)	1 / 21 (4.76%)
occurrences (all)	2	1	1
Skin ulcer			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Urticaria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Vitiligo			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Xeroderma			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	2 / 21 (9.52%)
occurrences (all)	0	2	2
Micturition urgency			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Nocturia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Pollakiuria			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	2 / 21 (9.52%)
occurrences (all)	0	2	2
Proteinuria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Renal tubular necrosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Urinary incontinence			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0

Urinary retention subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 42 (2.38%) 1	0 / 21 (0.00%) 0
Urinary tract pain subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 42 (0.00%) 0	1 / 21 (4.76%) 1
Urine abnormality subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 42 (2.38%) 1	0 / 21 (0.00%) 0
Endocrine disorders			
Adrenal insufficiency subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	1 / 42 (2.38%) 2	0 / 21 (0.00%) 0
Hypercalcaemia of malignancy subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 42 (2.38%) 4	0 / 21 (0.00%) 0
Hyperthyroidism subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	1 / 42 (2.38%) 1	1 / 21 (4.76%) 1
Hypothyroidism subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	4 / 42 (9.52%) 4	2 / 21 (9.52%) 2
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	10 / 42 (23.81%) 18	7 / 21 (33.33%) 12
Arthritis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 42 (0.00%) 0	0 / 21 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	10 / 42 (23.81%) 11	2 / 21 (9.52%) 2
Bone lesion subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 42 (2.38%) 1	0 / 21 (0.00%) 0
Flank pain			

subjects affected / exposed	0 / 4 (0.00%)	4 / 42 (9.52%)	1 / 21 (4.76%)
occurrences (all)	0	5	1
Groin pain			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	1 / 21 (4.76%)
occurrences (all)	0	1	1
Joint range of motion decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Joint swelling			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Limb discomfort			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 4 (0.00%)	6 / 42 (14.29%)	2 / 21 (9.52%)
occurrences (all)	0	6	2
Muscular weakness			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	3 / 21 (14.29%)
occurrences (all)	0	1	3
Musculoskeletal chest pain			
subjects affected / exposed	1 / 4 (25.00%)	4 / 42 (9.52%)	1 / 21 (4.76%)
occurrences (all)	1	6	1
Musculoskeletal pain			
subjects affected / exposed	0 / 4 (0.00%)	5 / 42 (11.90%)	1 / 21 (4.76%)
occurrences (all)	0	6	1
Musculoskeletal stiffness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Myalgia			
subjects affected / exposed	0 / 4 (0.00%)	6 / 42 (14.29%)	3 / 21 (14.29%)
occurrences (all)	0	9	3
Neck pain			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	1 / 21 (4.76%)
occurrences (all)	0	1	1
Osteoarthritis			

subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Pain in extremity			
subjects affected / exposed	0 / 4 (0.00%)	6 / 42 (14.29%)	4 / 21 (19.05%)
occurrences (all)	0	7	5
Pain in jaw			
subjects affected / exposed	1 / 4 (25.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Pathological fracture			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Spinal pain			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Tendon disorder			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Infections and infestations			
Abscess			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Bronchiolitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Bronchitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	2	0
Conjunctivitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Ear infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Eye infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1

Gastrointestinal fungal infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Gingivitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Herpes zoster			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Hordeolum			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Influenza			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Kidney infection			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	2	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Lower respiratory tract infection bacterial			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Nasopharyngitis			
subjects affected / exposed	0 / 4 (0.00%)	3 / 42 (7.14%)	0 / 21 (0.00%)
occurrences (all)	0	3	0
Oral candidiasis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Oral fungal infection			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Oral herpes			

subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	0 / 21 (0.00%)
occurrences (all)	0	2	0
Otitis media			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Pneumonia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Rash pustular			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Respiratory tract infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	2
Rhinitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Sinusitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	2 / 21 (9.52%)
occurrences (all)	0	0	3
Tooth abscess			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Tooth infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Upper respiratory tract infection			
subjects affected / exposed	0 / 4 (0.00%)	3 / 42 (7.14%)	0 / 21 (0.00%)
occurrences (all)	0	5	0
Urinary tract infection			
subjects affected / exposed	1 / 4 (25.00%)	2 / 42 (4.76%)	4 / 21 (19.05%)
occurrences (all)	1	2	5
Viral infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Viral upper respiratory tract infection			

subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 42 (0.00%) 0	0 / 21 (0.00%) 0
Metabolism and nutrition disorders			
Acidosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Decreased appetite			
subjects affected / exposed	0 / 4 (0.00%)	5 / 42 (11.90%)	1 / 21 (4.76%)
occurrences (all)	0	5	1
Dehydration			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	1 / 21 (4.76%)
occurrences (all)	0	3	2
Glucose tolerance impaired			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	1 / 21 (4.76%)
occurrences (all)	0	1	1
Gout			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Hypercalcaemia			
subjects affected / exposed	0 / 4 (0.00%)	6 / 42 (14.29%)	2 / 21 (9.52%)
occurrences (all)	0	9	2
Hyperglycaemia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Hyperkalaemia			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	2 / 21 (9.52%)
occurrences (all)	0	3	5
Hypermagnesaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
Hypertriglyceridaemia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Hyperuricaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0

Hypoalbuminaemia			
subjects affected / exposed	0 / 4 (0.00%)	2 / 42 (4.76%)	0 / 21 (0.00%)
occurrences (all)	0	3	0
Hypocalcaemia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Hypoglycaemia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Hypokalaemia			
subjects affected / exposed	0 / 4 (0.00%)	5 / 42 (11.90%)	2 / 21 (9.52%)
occurrences (all)	0	6	2
Hypomagnesaemia			
subjects affected / exposed	0 / 4 (0.00%)	4 / 42 (9.52%)	2 / 21 (9.52%)
occurrences (all)	0	9	6
Hyponatraemia			
subjects affected / exposed	0 / 4 (0.00%)	3 / 42 (7.14%)	1 / 21 (4.76%)
occurrences (all)	0	4	5
Hypophosphataemia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	3 / 21 (14.29%)
occurrences (all)	0	1	8
Metabolic alkalosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 42 (0.00%)	1 / 21 (4.76%)
occurrences (all)	0	0	1
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 4 (0.00%)	1 / 42 (2.38%)	0 / 21 (0.00%)
occurrences (all)	0	2	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
16 April 2014	Name AMP 514 was replaced with MEDI0680. Specified that immunotherapy-naïve and pretreated participants were to be enrolled in up to 8 hematologic and solid tumor cohorts and that the immunotherapy naïve and pretreated cohorts could enroll an additional 60 participants based on emerging efficacy and safety data from the current study and ongoing studies. Specified that each hematologic cohort, including MDS, would only be expanded after submission of a formal protocol amendment. Updated the inclusion criteria to include NSCLC participants must have failed to respond or relapsed following platinum containing doublet chemotherapy.
01 October 2014	To align with strategy of study focus the tumor types were limited to non-small cell lung cancer, squamous cell carcinoma of the head and neck, microsatellite instability-high colorectal cancer, bladder cancer, ovarian cancer, esophageal cancer, gastric cancer, and renal cell carcinoma in the dose-escalation phase. Added 20 mg/kg MEDI0680 plus 10 mg/kg durvalumab cohort to the Q2W dose-escalation schedule. Revised the dose-escalation phase to allow for any dose-escalation cohort that has not exceeded the MTD to be expanded by up to a maximum of 18 participants. Updated the inclusion criteria as: Revised to reflect the solid tumor types that would be allowed in the dose escalation phase. Indicated that no more than 3 prior lines of systemic therapy would be allowed in the recurrent or metastatic setting; added specific inclusion criteria for NSCLC participants in dose-escalation and dose-expansion; and added that participants with previously treated CNS metastases must be radiographically and neurologically stable for at least 6 weeks.
11 February 2016	Dose-expansion phase updated to enroll PD-L1 positive immunotherapy-naïve participants with RCC, added MEDI0680 monotherapy as a comparator arm; revised primary objective to evaluate antitumor activity based on investigator assessed response and secondary objectives to describe safety and tolerability, and to evaluate antitumor activity based on BICR assessed response in immunotherapy-naïve participants with advanced or metastatic ccRCC. Removed exploratory objective on patient reported outcomes. Replaced primary endpoint of maximum tolerated dose with presence of AEs, SAEs, laboratory parameters, vital signs, physical examinations, and ECG results. Added endpoint of PD-L1 expression/localization on tumor membrane and tumor infiltrating immune cells within tumor microenvironment. Increased sample size to 156 and study centers to 80. Participants in dose expansion phase were not to be replaced. Updated safety assessment. Added Appendix of Dose Modifications for Toxicity Management.
27 May 2016	Revised the exclusion criteria to permit enrollment of participants with prior endocrine toxicities who are stable on replacement therapy.
29 March 2017	Removed MEDI0680 monotherapy arm in the dose-expansion phase and replaced with a nivolumab monotherapy arm. Clarified that OR is the primary endpoint and that OS is a secondary endpoint in the dose expansion phase. Reduced the planned sample size from 156 to approximately 96 participants for both dose-escalation and dose-expansion phases; from 120 to approximately 60 in dose-expansion phases; and study center numbers from 80 to 50. Added an interim futility analysis for the MEDI0680/durvalumab combination therapy arm in the dose-expansion phase after 20 participants have been randomized and have reached their second post baseline disease assessment or have completed the study. Changed the randomization ratio of combination and monotherapy from 1:1 to 2:1. Revised end of study definition from 3 years to 2 years after the last participant was enrolled and added possible treatment options for participants still receiving treatment at the end of the study.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Study did not meet primary endpoint, so, BICR data for antitumor activity were not collected. Numeric data were not collected for "Change from baseline in target lesion" as it was to be analysed by Spider plots per Statistical Analysis Plan.

Notes: